risperidone has been researched along with Aggression in 187 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Aggression: Behavior which may be manifested by destructive and attacking action which is verbal or physical, by covert attitudes of hostility or by obstructionism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To conduct a feasibility randomised controlled trial of risperidone for the treatment of aggression in adults with traumatic brain injury (TBI)." | 9.34 | Risperidone versus placebo for aggression following traumatic brain injury: a feasibility randomised controlled trial. ( Aimola, L; Bassett, P; Bodani, M; Crawford, M; Deb, S; Leeson, V; Li, L; Sharp, D; Weaver, T, 2020) |
| "We will examine the feasibility of conducting a placebo-controlled, double-blind RCT of risperidone for the management of aggression in adults with TBI and also assess participants' views about their experience of taking part in the study." | 9.27 | Aggression Following Traumatic brain injury: Effectiveness of Risperidone (AFTER): study protocol for a feasibility randomised controlled trial. ( Aimola, L; Bodani, M; Crawford, M; Deb, S; Leeson, V; Li, L; Sharp, D; Weaver, T, 2018) |
| "Although the nonrandomized, nonblind design limits the conclusions of our exploratory study, our findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms." | 9.24 | A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( Manfredi, A; Masi, G; Milone, A; Muratori, P; Nieri, G; Pfanner, C, 2017) |
| "Risperidone is a common psychopharmacological treatment for irritability in autism spectrum disorder (ASD)." | 9.22 | Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. ( Furukawa, TA; Goldberg, Y; Kodesh, A; Kolevzon, A; Leucht, S; Levine, SZ; Reichenberg, A, 2016) |
| "A total of 168 children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder (ADHD) were enrolled in a 9-week trial of basic treatment (n=84, stimulant+parent training+placebo) versus augmented treatment (n=84, stimulant+parent training+risperidone)." | 9.20 | Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. ( Aman, MG; Arnold, LE; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Kolko, DG; McNamara, N; Molina, BS; Rice, RR; Rundberg-Rivera, EV, 2015) |
| "In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms." | 9.20 | Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. ( Aman, MG; Arnold, LE; Bangalore, S; Brown, NV; Buchan-Page, K; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Hurt, EA; Li, X; McNamara, NK; Molina, BS; Rice, R; Rundberg-Rivera, EV, 2015) |
| "TOSCA was a randomized clinical trial of psychostimulant plus parent training plus placebo (basic treatment) versus psychostimulant plus parent training plus risperidone (augmented treatment) for children with severe physical aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder." | 9.20 | Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. ( Aman, MG; Arnold, LE; Austin, A; Buchan-Page, KA; Bukstein, OG; Farmer, CA; Findling, RL; Gadow, KD; Kipp, H; Kolko, DJ; McNamara, NK; Michel, C; Molina, BB; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Townsend, LD, 2015) |
| "Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism." | 9.20 | Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. ( Aman, M; Arnold, LE; Ghuman, J; Grados, M; Hellings, J; Hollway, JA; McCracken, J; McDougle, CJ; Nagaraja, HN; Posey, DJ; Rettiganti, M; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2015) |
| " The value of adding risperidone to concurrent psychostimulant and parent training (PT) in behavior management for children with severe aggression was tested." | 9.19 | What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? ( Aman, MG; Arnold, LE; Austin, AB; Baker, J; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, H; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "In this study, we aimed to expand on our prior research into the relative efficacy of combining parent training, stimulant medication, and placebo (Basic therapy) versus parent training, stimulant, and risperidone (Augmented therapy) by examining treatment effects for attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and conduct disorder (CD) symptoms and peer aggression, symptom-induced impairment, and informant discrepancy." | 9.19 | Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. ( Aman, MG; Arnold, LE; Austin, AB; Baker, JL; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, HL; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "62 subjects with intellectual disability underwent to a 2-arm, parallel group pragmatic trial of olanzapine and risperidone with balanced randomisation and blind assessment of outcome at 4, 8, 12, 16, 20 and 24 weeks after a switch (cross-tapering) from a 24-week treatment with FGAs." | 9.15 | Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study. ( Amore, M; Bertelli, M; Rossi, M; Tamborini, S; Villani, D, 2011) |
| "To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD)." | 9.12 | Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. ( Armenteros, JL; Davalos, M; Lewis, JE, 2007) |
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 9.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode." | 9.11 | Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. ( Casey, DE; Citrome, L; Daniel, DG; Kochan, LD; Tracy, KA; Wozniak, P, 2004) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 9.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "Risperidone is effective for short-term treatment of aggression, temper outbursts, and self-injurious behavior in children with autism." | 9.11 | Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. ( , 2005) |
| "As monotherapy, both olanzapine and risperidone were superior to haloperidol and clozapine in reducing aggression." | 9.11 | Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). ( Bitter, I; Czobor, P; Dossenbach, M; Volavka, J, 2005) |
| "The present study aimed to analyse the effect of risperidone on a priori defined core aggression items." | 9.11 | Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. ( Aman, MG; Armenteros, JL; Binder, CE; Hew, H; Kusumakar, V; LeBlanc, JC; Wang, JS, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 9.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "This randomized, double-blind, placebo-controlled trial examined the efficacy and safety of risperidone in the treatment of aggression, agitation, and psychosis in elderly nursing-home patients with dementia." | 9.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| " This study tested the hypothesis that low-dose risperidone reduces aggression and other PTSD-related symptoms in combat veterans." | 9.10 | Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. ( Ciraulo, DA; Keane, T; Knapp, C; Monnelly, EP, 2003) |
| "In the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network 8-week double-blind trial of risperidone versus placebo, the chief concerns of parents were collected at 0, 4, and 8 weeks (endpoint), in addition to standardized primary measures." | 9.10 | Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. ( Aman, MG; Arnold, LE; Chuang, S; Cronin, P; Davies, M; Gonzalez, NM; Hollway, J; Koenig, K; Kohn, AE; McDougle, C; McMahon, DJ; Scahill, L; Shah, B; Tierney, E; Vitiello, B, 2003) |
| "We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia." | 9.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "Risperidone was superior to placebo in ameliorating aggression on most measures." | 9.09 | A double-blind pilot study of risperidone in the treatment of conduct disorder. ( Blumer, JL; Branicky, LA; Findling, RL; Lemon, E; McNamara, NK; Schluchter, MD, 2000) |
| "We randomly assigned 38 adolescents (33 boys; 10 subjects with slightly subaverage IQ, 14 with borderline IQ, and 14 with mild mental retardation), who were hospitalized for treatment of psychiatric disorders associated with severe aggression, to receive risperidone or placebo." | 9.09 | A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. ( Buitelaar, JK; Cohen-Kettenis, P; Melman, CT; van der Gaag, RJ, 2001) |
| "As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit." | 9.09 | Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. ( Crandall, K; Hellings, JA; Schroeder, SR; Wallace, D; Zarcone, JR, 2001) |
| "The authors describe a series of 22 patients with dementia and behavioral disturbances, including agitation, aggression, delusions, and hallucinations, who were treated with risperidone." | 9.08 | Risperidone for the treatment of behavioral disturbances in dementia: a case series. ( Campbell, B; Flynn, M; Herrmann, N; Rabheru, K; Rivard, MF; Ward, C, 1998) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 9.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 8.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "MEDLINE and EMBASE databases were used to identify controlled studies of risperidone in the treatment of disruptive behavior disorders and pervasive developmental disorders in pediatric patients, acute agitation or aggression in adults, and psychological and behavioral symptoms of dementia in the elderly." | 8.83 | Risperidone in the management of agitation and aggression associated with psychiatric disorders. ( Buitelaar, J; De Deyn, PP, 2006) |
| " In the present quantitative review the published evidence regarding the effects of risperidone on hostility and aggression in schizophrenia is evaluated." | 8.81 | Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. ( Aleman, A; Kahn, RS, 2001) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 8.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "The efficacy of risperidone has been demonstrated in the treatment of the behavioural and psychological symptoms associated with dementia in the elderly." | 8.80 | Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. ( Bhana, N; Spencer, CM, 2000) |
| "Risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation." | 7.85 | Mild Hypothermia in a Child with Low-Dose Risperidone. ( Denzer, C; Freudenmann, RW; Gahr, M; Grau, K; Plener, PL, 2017) |
| "Risperidone has been shown to be clinically effective for the treatment of aggressive behavior in children, yet until recently no information was available regarding whether risperidone exhibits aggression-specific suppression in preclinical studies employing validated developmentally immature animal models of escalated aggression." | 7.74 | Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, RL; Ricci, LA; Schwartzer, JJ, 2008) |
| "Risperidone has been shown to be clinically effective for the treatment of aggressive behavior in children, yet no information is available regarding whether risperidone exhibits aggression-specific suppression in preclinical studies that use validated developmentally immature animal models of escalated aggression." | 7.74 | Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, R; Ricci, LA, 2007) |
| "Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia." | 7.73 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. ( Gonen, N; Kupchik, M; Mester, R; Roitman, S; Schwartz, S; Spivak, B; Strous, RD; Weizman, A, 2006) |
| "To evaluate the effectiveness and safety of risperidone in children and adolescents with bipolar disorder characterized by aggression and mania, despite treatment with mood stabilizers." | 7.73 | Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. ( Chang, K; Saxena, K; Steiner, H, 2006) |
| "The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders." | 7.72 | No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. ( Biederman, J; Bourgeois, BF; Fleisher, CA; Gonzalez-Heydrich, J; Hsin, O; Pandina, GJ; Raches, D, 2004) |
| "The current investigation lends support to data that note weight gain with risperidone in adults with mental retardation." | 7.71 | Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. ( Cohen, S; Glazewski, R; Khan, A; Khan, S, 2001) |
| "The observed effect of risperidone on aggression is in concordance with other reports, but in lower dosages than reported elsewhere." | 7.71 | [Risperidone as a tool to control hard aggression]. ( Heitun, OG, 2001) |
| "Clozapine is effective in up to 60% of patients with refractory schizophrenia, whereas the efficacy of risperidone remains unknown." | 7.70 | Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. ( Ratakonda, SS; Raza, A; Sharif, ZA, 2000) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 6.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "The treatment with risperidone was well tolerated." | 6.72 | [Changeover to risperidone after treatment with conventional low potency neuroleptics in dementia patients. An observation study during usage]. ( Schmitt, AB; Schreiner, A; Stoppe, G, 2006) |
| " This study examined the effect of electroconvulsive therapy (ECT) in combination with risperidone in an open trial in 10 male schizophrenic patients with significant aggressive behaviors." | 6.70 | Effectiveness of ECT combined with risperidone against aggression in schizophrenia. ( Ashby, CR; Hirose, S; Mills, MJ, 2001) |
| "Of the various Axis II disorders, borderline personality disorder (BPD) is among the more critical to treat." | 6.70 | Treatment of borderline personality disorder with risperidone. ( Bogetto, F; Cocuzza, E; Marchiaro, L; Rocca, P, 2002) |
| "Risperidone doses were low (0." | 6.69 | Risperidone for young children with mood disorders and aggressive behavior. ( Schreier, HA, 1998) |
| "To conduct a feasibility randomised controlled trial of risperidone for the treatment of aggression in adults with traumatic brain injury (TBI)." | 5.34 | Risperidone versus placebo for aggression following traumatic brain injury: a feasibility randomised controlled trial. ( Aimola, L; Bassett, P; Bodani, M; Crawford, M; Deb, S; Leeson, V; Li, L; Sharp, D; Weaver, T, 2020) |
| "Risperidone was effective in reducing destructive behavior (compared to placebo) for 10 participants." | 5.32 | Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. ( Crosland, KA; Hellings, JA; Lindauer, SE; Matthew Reese, R; McKerchar, TL; Morse, PS; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2004) |
| "The risperidone was started at 0." | 5.30 | Risperidone and explosive aggressive autism. ( Barnhill, LJ; Horrigan, JP, 1997) |
| "Risperidone has proven efficacy with reduced likelihood of causing extrapyramidal symptoms in the treatment of schizophrenia." | 5.30 | Risperidone for aggression and self-injurious behavior in adults with mental retardation. ( Cohen, SA; Ihrig, K; Kerrick, JM; Lott, RS, 1998) |
| "We will examine the feasibility of conducting a placebo-controlled, double-blind RCT of risperidone for the management of aggression in adults with TBI and also assess participants' views about their experience of taking part in the study." | 5.27 | Aggression Following Traumatic brain injury: Effectiveness of Risperidone (AFTER): study protocol for a feasibility randomised controlled trial. ( Aimola, L; Bodani, M; Crawford, M; Deb, S; Leeson, V; Li, L; Sharp, D; Weaver, T, 2018) |
| "Although the nonrandomized, nonblind design limits the conclusions of our exploratory study, our findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms." | 5.24 | A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( Manfredi, A; Masi, G; Milone, A; Muratori, P; Nieri, G; Pfanner, C, 2017) |
| "The Treatment of Severe Childhood Aggression (TOSCA) project examined augmentation of stimulant treatment and parent training (PT) with risperidone for severe physical aggression." | 5.24 | Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. ( Aman, MG; Arnold, LE; Barterian, JA; Brown, NV; Bukstein, OG; Farmer, CA; Findling, RL; Kolko, DJ; Molina, BSG; Townsend, L; Williams, C, 2017) |
| "Risperidone is a common psychopharmacological treatment for irritability in autism spectrum disorder (ASD)." | 5.22 | Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. ( Furukawa, TA; Goldberg, Y; Kodesh, A; Kolevzon, A; Leucht, S; Levine, SZ; Reichenberg, A, 2016) |
| "The objective of this study was to evaluate 52-week clinical outcomes of children with co-occurring attention-deficit/hyperactivity disorder (ADHD), disruptive behavior disorder, and serious physical aggression who participated in a prospective, longitudinal study that began with a controlled, 9-week clinical trial comparing the relative efficacy of parent training + stimulant medication + placebo (Basic; n = 84) versus parent training + stimulant + risperidone (Augmented; n = 84)." | 5.22 | Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. ( Aman, MG; Arnold, LE; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, E; Farmer, CA; Findling, RL; Gadow, KD; Kolko, DJ; Molina, BS; Rice, RR; Schneider, J, 2016) |
| "A total of 168 children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder (ADHD) were enrolled in a 9-week trial of basic treatment (n=84, stimulant+parent training+placebo) versus augmented treatment (n=84, stimulant+parent training+risperidone)." | 5.20 | Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. ( Aman, MG; Arnold, LE; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Kolko, DG; McNamara, N; Molina, BS; Rice, RR; Rundberg-Rivera, EV, 2015) |
| "In the four-site Treatment of Severe Childhood Aggression (TOSCA) study, addition of risperidone to stimulant and parent training moderately improved parent-rated disruptive behavior disorder (DBD) symptoms." | 5.20 | Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. ( Aman, MG; Arnold, LE; Bangalore, S; Brown, NV; Buchan-Page, K; Bukstein, O; Farmer, CA; Findling, RL; Gadow, KD; Hurt, EA; Li, X; McNamara, NK; Molina, BS; Rice, R; Rundberg-Rivera, EV, 2015) |
| "TOSCA was a randomized clinical trial of psychostimulant plus parent training plus placebo (basic treatment) versus psychostimulant plus parent training plus risperidone (augmented treatment) for children with severe physical aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder." | 5.20 | Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. ( Aman, MG; Arnold, LE; Austin, A; Buchan-Page, KA; Bukstein, OG; Farmer, CA; Findling, RL; Gadow, KD; Kipp, H; Kolko, DJ; McNamara, NK; Michel, C; Molina, BB; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Townsend, LD, 2015) |
| "Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism." | 5.20 | Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. ( Aman, M; Arnold, LE; Ghuman, J; Grados, M; Hellings, J; Hollway, JA; McCracken, J; McDougle, CJ; Nagaraja, HN; Posey, DJ; Rettiganti, M; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2015) |
| "This study identified subtypes of aggression in a sample of 206 children with autism spectrum disorder (ASD) who participated in 2 risperidone trials." | 5.19 | Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems. ( Aman, MG; Arnold, LE; Bearss, K; Carroll, D; Hallett, V; Handen, BL; Johnson, C; Lecavalier, L; McCracken, JT; McDougle, CJ; Scahill, L; Sukhodolsky, DG; Swiezy, N; Tierney, E; Vitiello, B, 2014) |
| "Our results are consistent with those of a similar post-hoc analysis of hostility in first-episode subjects with schizophrenia enrolled in the European First-Episode Schizophrenia Trial (EUFEST) trial, where olanzapine demonstrated advantages compared with haloperidol, quetiapine, and amisulpride." | 5.19 | Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. ( Citrome, L; Czobor, P; Van Dorn, RA; Volavka, J, 2014) |
| " The value of adding risperidone to concurrent psychostimulant and parent training (PT) in behavior management for children with severe aggression was tested." | 5.19 | What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? ( Aman, MG; Arnold, LE; Austin, AB; Baker, J; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, H; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "In this study, we aimed to expand on our prior research into the relative efficacy of combining parent training, stimulant medication, and placebo (Basic therapy) versus parent training, stimulant, and risperidone (Augmented therapy) by examining treatment effects for attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), and conduct disorder (CD) symptoms and peer aggression, symptom-induced impairment, and informant discrepancy." | 5.19 | Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. ( Aman, MG; Arnold, LE; Austin, AB; Baker, JL; Bangalore, SS; Brown, NV; Buchan-Page, KA; Bukstein, OG; Butter, EM; Farmer, CA; Findling, RL; Gadow, KD; Grondhuis, SN; Hurt, EA; Kipp, HL; Li, X; McNamara, NK; Molina, BS; Rice, RR; Rundberg-Rivera, EV; Schneider, J; Sprafkin, J, 2014) |
| "Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks." | 5.16 | Relapse risk after discontinuation of risperidone in Alzheimer's disease. ( Andrews, HF; Colon, S; de la Pena, D; Devanand, DP; Gupta, S; Levin, B; Mintzer, J; Pelton, GH; Schimming, C; Schultz, SK; Sultzer, DL, 2012) |
| "62 subjects with intellectual disability underwent to a 2-arm, parallel group pragmatic trial of olanzapine and risperidone with balanced randomisation and blind assessment of outcome at 4, 8, 12, 16, 20 and 24 weeks after a switch (cross-tapering) from a 24-week treatment with FGAs." | 5.15 | Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study. ( Amore, M; Bertelli, M; Rossi, M; Tamborini, S; Villani, D, 2011) |
| " Aggression decreased substantially with all three treatments by 4 weeks, with the placebo group showing the greatest change (median decrease in MOAS score after 4 weeks=9 [95% CI 5-14] for placebo, 79% from baseline; 7 [4-14] for risperidone, 58% from baseline; 6." | 5.13 | Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. ( Ahmed, Z; Bhaumik, S; Bouras, N; Cooray, S; Crawford, M; Deb, S; Eliahoo, J; Hare, M; Harley, D; Karatela, S; Kramo, K; Meade, M; Murphy, D; North, B; Oliver-Africano, PC; Rao, B; Reece, B; Regan, A; Soni, A; Thomas, D; Tyrer, P, 2008) |
| "To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD)." | 5.12 | Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. ( Armenteros, JL; Davalos, M; Lewis, JE, 2007) |
| "The objective of the study was to compare the antiaggressive efficacy of risperidone monotherapy versus risperidone plus valproate in patients with schizophrenia." | 5.12 | Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. ( Citrome, L; Czobor, P; Nolan, KA; Shope, CB; Volavka, J, 2007) |
| "This study compared the specific antihostility effects of atypical antipsychotic monotherapy (olanzapine or risperidone) with that of combination treatment with divalproex sodium among patients with schizophrenia experiencing an acute psychotic episode." | 5.11 | Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. ( Casey, DE; Citrome, L; Daniel, DG; Kochan, LD; Tracy, KA; Wozniak, P, 2004) |
| "To examine the effect of risperidone on specific behavioral and psychological symptoms of dementia (BPSD)." | 5.11 | Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. ( Brodaty, H; Davidson, M; De Deyn, PP; Greenspan, A; Katz, IR; Rabinowitz, J, 2004) |
| "To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders (PDD)." | 5.11 | Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. ( Carroll, A; Dunbar, F; Orlik, H; Schulz, M; Shea, S; Smith, I; Turgay, A, 2004) |
| "Risperidone is effective for short-term treatment of aggression, temper outbursts, and self-injurious behavior in children with autism." | 5.11 | Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. ( , 2005) |
| "As monotherapy, both olanzapine and risperidone were superior to haloperidol and clozapine in reducing aggression." | 5.11 | Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO). ( Bitter, I; Czobor, P; Dossenbach, M; Volavka, J, 2005) |
| "The present study aimed to analyse the effect of risperidone on a priori defined core aggression items." | 5.11 | Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials. ( Aman, MG; Armenteros, JL; Binder, CE; Hew, H; Kusumakar, V; LeBlanc, JC; Wang, JS, 2005) |
| "Risperidone significantly improves behavioral and psychological symptoms of dementia (BPSD), including aggression, agitation and psychosis, as shown by randomized, placebo-controlled trials." | 5.11 | Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice. ( Kurz, A; Schmitt, A; Schwalen S, S, 2005) |
| "This randomized, double-blind, placebo-controlled trial examined the efficacy and safety of risperidone in the treatment of aggression, agitation, and psychosis in elderly nursing-home patients with dementia." | 5.10 | A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. ( Ames, D; Brodaty, H; Clarnette, R; Grossman, F; Kirwan, J; Lee, E; Lyons, B; Snowdon, J; Woodward, M, 2003) |
| " This study tested the hypothesis that low-dose risperidone reduces aggression and other PTSD-related symptoms in combat veterans." | 5.10 | Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. ( Ciraulo, DA; Keane, T; Knapp, C; Monnelly, EP, 2003) |
| "The atypical antipsychotic medication risperidone was evaluated using a double-blind, placebo-controlled design in the treatment of destructive behavior in two individuals with autism." | 5.10 | Use of functional analysis methodology in the evaluation of medication effects. ( Crosland, KA; Hellings, JA; Lindauer, SE; Schroeder, SR; Valdovinos, MG; Zarcone, JR; Zarcone, TJ, 2003) |
| "In the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network 8-week double-blind trial of risperidone versus placebo, the chief concerns of parents were collected at 0, 4, and 8 weeks (endpoint), in addition to standardized primary measures." | 5.10 | Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. ( Aman, MG; Arnold, LE; Chuang, S; Cronin, P; Davies, M; Gonzalez, NM; Hollway, J; Koenig, K; Kohn, AE; McDougle, C; McMahon, DJ; Scahill, L; Shah, B; Tierney, E; Vitiello, B, 2003) |
| "We report the findings from the first large, double-blind, placebo-controlled study conducted to evaluate the efficacy and safety of risperidone in the treatment of psychotic and behavioral symptoms in institutionalized elderly patients with dementia." | 5.09 | Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. ( Brecher, M; Clyde, C; Jeste, DV; Katz, IR; Mintzer, JE; Napolitano, J, 1999) |
| "Risperidone was superior to placebo in ameliorating aggression on most measures." | 5.09 | A double-blind pilot study of risperidone in the treatment of conduct disorder. ( Blumer, JL; Branicky, LA; Findling, RL; Lemon, E; McNamara, NK; Schluchter, MD, 2000) |
| "We randomly assigned 38 adolescents (33 boys; 10 subjects with slightly subaverage IQ, 14 with borderline IQ, and 14 with mild mental retardation), who were hospitalized for treatment of psychiatric disorders associated with severe aggression, to receive risperidone or placebo." | 5.09 | A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. ( Buitelaar, JK; Cohen-Kettenis, P; Melman, CT; van der Gaag, RJ, 2001) |
| "As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit." | 5.09 | Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. ( Crandall, K; Hellings, JA; Schroeder, SR; Wallace, D; Zarcone, JR, 2001) |
| "This study examines the effectiveness of risperidone compared with traditional neuroleptic medications in the areas of clinical functioning and aggressive behaviors in a sample of inpatients diagnosed with chronic schizophrenia." | 5.08 | Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. ( Beck, NC; Gotham, H; Greenfield, SR; Hemme, CA; Menditto, AA; Stuve, P, 1997) |
| "The authors describe a series of 22 patients with dementia and behavioral disturbances, including agitation, aggression, delusions, and hallucinations, who were treated with risperidone." | 5.08 | Risperidone for the treatment of behavioral disturbances in dementia: a case series. ( Campbell, B; Flynn, M; Herrmann, N; Rabheru, K; Rivard, MF; Ward, C, 1998) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 5.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| " Risperidone is a widely accessible antipsychotic that can be used to manage psychosis-induced aggression or agitation." | 4.98 | Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). ( Adams, CE; Ahmed, U; Hussein, M; Miramontes, K; Ostinelli, EG; Rehman, FU, 2018) |
| "There is some evidence that in the short term risperidone may reduce aggression and conduct problems in children and youths with disruptive behaviour disorders There is also evidence that this intervention is associated with significant weight gain." | 4.95 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2017) |
| "Antipsychotics, particularly risperidone, appear to be effective in reducing problem behaviors in children with intellectual disability." | 4.93 | Pharmacotherapy for mental health problems in people with intellectual disability. ( Findling, RL; Ji, NY, 2016) |
| "There is some limited evidence of efficacy of risperidone reducing aggression and conduct problems in children aged 5 to 18 with disruptive behaviour disorders in the short term." | 4.88 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2012) |
| "MEDLINE and EMBASE databases were used to identify controlled studies of risperidone in the treatment of disruptive behavior disorders and pervasive developmental disorders in pediatric patients, acute agitation or aggression in adults, and psychological and behavioral symptoms of dementia in the elderly." | 4.83 | Risperidone in the management of agitation and aggression associated with psychiatric disorders. ( Buitelaar, J; De Deyn, PP, 2006) |
| " There was a significant improvement in aggression with risperidone and olanzapine treatment compared to placebo." | 4.83 | The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. ( Ballard, C; Waite, J, 2006) |
| " In the present quantitative review the published evidence regarding the effects of risperidone on hostility and aggression in schizophrenia is evaluated." | 4.81 | Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. ( Aleman, A; Kahn, RS, 2001) |
| "Risperidone offers physicians the unique combination of extensive, published clinical experience and a good safety profile for treating patients with dementia who have symptoms of aggression, agitation, and psychosis." | 4.81 | Risperidone for the treatment of behavioral and psychological symptoms of dementia. ( Tune, LE, 2001) |
| "The efficacy of risperidone has been demonstrated in the treatment of the behavioural and psychological symptoms associated with dementia in the elderly." | 4.80 | Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia. ( Bhana, N; Spencer, CM, 2000) |
| "Risperidone is a widely used, second-generation antipsychotic approved for treating schizophrenia as well as for treating aggression in children and adolescents with mental retardation." | 3.85 | Mild Hypothermia in a Child with Low-Dose Risperidone. ( Denzer, C; Freudenmann, RW; Gahr, M; Grau, K; Plener, PL, 2017) |
| "Risperidone's beneficial effect on aggression and other elements of adaptive functioning were not necessarily accompanied by reduction in core ASD symptoms, as serially assessed by the same caregivers who reported improvement in their children." | 3.80 | Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study. ( Constantino, JN; Marrus, N; Randall, F; Underwood-Riordan, H; Zhang, Y, 2014) |
| "Risperidone has been shown to be clinically effective for the treatment of aggressive behavior in children, yet until recently no information was available regarding whether risperidone exhibits aggression-specific suppression in preclinical studies employing validated developmentally immature animal models of escalated aggression." | 3.74 | Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, RL; Ricci, LA; Schwartzer, JJ, 2008) |
| " The present study investigated and confirmed significant sensitivity of the model to the aggression-lowering ability of the antipsychotic agent risperidone (CAS 106266-06-2)." | 3.74 | Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour. ( Coen, K; De Deyn, PP; Van Dam, D; Vloeberghs, E, 2008) |
| "Risperidone has been shown to be clinically effective for the treatment of aggressive behavior in children, yet no information is available regarding whether risperidone exhibits aggression-specific suppression in preclinical studies that use validated developmentally immature animal models of escalated aggression." | 3.74 | Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression. ( Connor, DF; Melloni, RH; Morrison, R; Ricci, LA, 2007) |
| "Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia." | 3.73 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. ( Gonen, N; Kupchik, M; Mester, R; Roitman, S; Schwartz, S; Spivak, B; Strous, RD; Weizman, A, 2006) |
| "To evaluate the effectiveness and safety of risperidone in children and adolescents with bipolar disorder characterized by aggression and mania, despite treatment with mood stabilizers." | 3.73 | Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series. ( Chang, K; Saxena, K; Steiner, H, 2006) |
| "The aim of this study was to study risperidone use in pediatric patients with comorbid epilepsy and psychiatric disorders." | 3.72 | No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. ( Biederman, J; Bourgeois, BF; Fleisher, CA; Gonzalez-Heydrich, J; Hsin, O; Pandina, GJ; Raches, D, 2004) |
| "The current investigation lends support to data that note weight gain with risperidone in adults with mental retardation." | 3.71 | Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. ( Cohen, S; Glazewski, R; Khan, A; Khan, S, 2001) |
| "The observed effect of risperidone on aggression is in concordance with other reports, but in lower dosages than reported elsewhere." | 3.71 | [Risperidone as a tool to control hard aggression]. ( Heitun, OG, 2001) |
| " A case of 'PANDAS' is presented to increase physician awareness of this disorder and to document effectiveness of risperidone in chorea and treatment-resistant disruptive behavior associated with this syndrome." | 3.70 | Risperidone in the treatment of choreiform movements and aggressiveness in a child with "PANDAS". ( Bhatara, VS; Kleinsasser, BJ; Misra, LK; Sanchez, JD, 1999) |
| "Clozapine is effective in up to 60% of patients with refractory schizophrenia, whereas the efficacy of risperidone remains unknown." | 3.70 | Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis. ( Ratakonda, SS; Raza, A; Sharif, ZA, 2000) |
| "Seventy-four patients (most with schizophrenia) met the inclusion criteria of the risperidone group." | 3.70 | Impact of risperidone on seclusion and restraint at a state psychiatric hospital. ( Atzert, R; Brar, JS; Brienzo, R; Chengappa, KN; Gopalani, A; Levine, J; Parepally, H; Ulrich, R, 2000) |
| "Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study); https://www." | 3.01 | Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization. ( Bailey, BY; Blader, JC; Carlson, GA; Crowell, JA; Daviss, WB; Foley, CA; Kafantaris, V; Margulies, DM; Matthews, TL; Pliszka, SR; Sauder, C; Sinha, C, 2021) |
| "Co-morbid diagnoses, such as disruptive behavior disorders (DBDs) and high levels of aggression, are extremely common among youth with pediatric bipolar disorder (PBD) and may interfere with treatment response; however, they have rarely been examined as predictors of response to pharmacotherapy." | 2.76 | Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder. ( Celio, CI; Henry, D; Pavuluri, MN; Weinstein, SM; West, AE, 2011) |
| "The treatment with risperidone was well tolerated." | 2.72 | [Changeover to risperidone after treatment with conventional low potency neuroleptics in dementia patients. An observation study during usage]. ( Schmitt, AB; Schreiner, A; Stoppe, G, 2006) |
| "Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies." | 2.72 | A crossover study of risperidone in children, adolescents and adults with mental retardation. ( Fleming, KK; Hellings, JA; Marquis, JG; Reese, RM; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2006) |
| " At the end of the observation, the mean dosage was 5." | 2.71 | [Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis]. ( Degner, D; Pajonk, FG; Peters, S; Rettig, K; Rüther, E; Schreiner, A, 2003) |
| "Lorazepam was administered to all of the patients assigned to risperidone and to 89% of those assigned to zuclopenthixol." | 2.71 | Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. ( Dries, PJ; Hovens, JE; Loonen, AJ; Melman, CT; Wapenaar, RJ, 2005) |
| "Risperidone was also associated with significantly greater improvement than placebo on all other Nisonger Child Behavior Rating Form subscales at endpoint, as well as on the Aberrant Behavior Checklist subscales for irritability, lethargy/social withdrawal, and hyperactivity; the Behavior Problems Inventory aggressive/destructive behavior subscale; a visual analogue scale of the most troublesome symptom; and the Clinical Global Impression change score." | 2.70 | Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. ( Aman, MG; De Smedt, G; Derivan, A; Findling, RL; Lyons, B, 2002) |
| " This study examined the effect of electroconvulsive therapy (ECT) in combination with risperidone in an open trial in 10 male schizophrenic patients with significant aggressive behaviors." | 2.70 | Effectiveness of ECT combined with risperidone against aggression in schizophrenia. ( Ashby, CR; Hirose, S; Mills, MJ, 2001) |
| "Of the various Axis II disorders, borderline personality disorder (BPD) is among the more critical to treat." | 2.70 | Treatment of borderline personality disorder with risperidone. ( Bogetto, F; Cocuzza, E; Marchiaro, L; Rocca, P, 2002) |
| "Risperidone doses were low (0." | 2.69 | Risperidone for young children with mood disorders and aggressive behavior. ( Schreier, HA, 1998) |
| "Risperidone was given in daily doses ranging from 0." | 2.69 | Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. ( Buitelaar, JK, 2000) |
| "Youth aggression is common and has a significant burden on individuals, families, and society." | 2.61 | Understanding Chronic Aggression and Its Treatment in Children and Adolescents. ( Magalotti, SR; McVoy, MK; Neudecker, M; Zaraa, SG, 2019) |
| "Schizophrenia is also associated with aggression directed at self and others." | 2.41 | The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. ( Keck, PE; McElroy, SL; Strakowski, SM, 2000) |
| "Patients with Alzheimer's disease exhibit aggressive behavior, and alterations in their serotonergic function have been identified." | 2.41 | Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. ( Mintzer, JE, 2001) |
| "25 mg/day (85 years, MMSE of 5), to 1 mg/day (75 years, MMSE of 15), with alternate day dosing required for those with slower drug clearance." | 1.62 | Towards safer risperidone prescribing in Alzheimer's disease. ( Bertrand, J; Bies, R; Bramon, E; Howard, R; Liu, KY; Otani, Y; Ozer, M; Pollock, BG; Reeves, S; Uchida, H; Yoshida, K, 2021) |
| " These data indicate that chronic administration of RISP and HAL impede behavioral recovery after TBI and impair performance in uninjured controls." | 1.35 | Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury. ( Cheng, JP; Hoffman, AN; Kline, AE; Massucci, JL; Zafonte, RD, 2008) |
| "Citalopram was the most preferred antidepressant and Carbamazepine, the most preferred mood stabilizer/antiepileptic." | 1.35 | Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey. ( Deb, S; Unwin, GL, 2008) |
| " During the subsequent week, rates of problem behavior typically decreased without reinstating the prior dosage of medication." | 1.34 | Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates. ( Dornbusch, K; Rapp, JT; Swanson, G, 2007) |
| " In addition, adverse events were also evaluated." | 1.34 | [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO]. ( Agoston, T; István, S; Tamás, T; Zoltán, J, 2007) |
| " Chronic administration of the synthetic gonadotropin (luteinising hormone) releasing hormone analogue, goserelin, reduces testosterone activity." | 1.33 | Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report. ( Raskind, MA; Rosin, RA, 2005) |
| "Memantine was initiated, and the dose was titrated to 10 mg twice daily." | 1.33 | Antipsychotic dose-sparing effect with addition of memantine. ( Sleeper, RB, 2005) |
| ""B" was an 11-year-old girl with mild mental retardation and aggression who was treated with risperidone 1 mg per day." | 1.32 | Risperidone-induced obsessive-compulsive symptoms in two children. ( Avci, A; Diler, RS; Scahill, L; Yolga, A, 2003) |
| "The structural background of mental retardation, the function of the affected cerebral structures, is not completely clarified." | 1.32 | [Experience with Risperidone in the treatment of institutionalized mentally retarded patients, with special reference to treatment of aggressive states]. ( Fehér, L; Hal, V, 2004) |
| "Risperidone was effective in reducing destructive behavior (compared to placebo) for 10 participants." | 1.32 | Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. ( Crosland, KA; Hellings, JA; Lindauer, SE; Matthew Reese, R; McKerchar, TL; Morse, PS; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2004) |
| " The failure to improve without an adequate dosage of LT4 suggests that hypothyroidism was probably an aggravating factor." | 1.32 | Coexistent hypothyroidism, psychosis, and severe obsessions in an adolescent: a 10-year follow-up. ( Alshari, MG; Bhatara, A; Bhatara, V; McMillin, JM; Warhol, P, 2004) |
| "Risperidone was used in combination with other psychotropic medications in 7 of the 8 children." | 1.31 | A case series of eight aggressive young children treated with risperidone. ( Cesena, M; DeMaso, DR; Gonzalez-Heydrich, J; Kohlenberg, TM; Szigethy, E, 2002) |
| "Risperidone is an atypical antipsychotic agent with dopamine and serotonin antagonistic effects." | 1.31 | Risperidone for controlling aggressive behavior in a mentally retarded child: a case report. ( Intaprasert, S; Maneeton, N; Srisurapanont, M, 2001) |
| "The risperidone was started at 0." | 1.30 | Risperidone and explosive aggressive autism. ( Barnhill, LJ; Horrigan, JP, 1997) |
| "Risperidone has proven efficacy with reduced likelihood of causing extrapyramidal symptoms in the treatment of schizophrenia." | 1.30 | Risperidone for aggression and self-injurious behavior in adults with mental retardation. ( Cohen, SA; Ihrig, K; Kerrick, JM; Lott, RS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (11.76) | 18.2507 |
| 2000's | 104 (55.61) | 29.6817 |
| 2010's | 52 (27.81) | 24.3611 |
| 2020's | 9 (4.81) | 2.80 |
| Authors | Studies |
|---|---|
| Baweja, R | 1 |
| Waxmonsky, JG | 1 |
| Hodgins, GE | 1 |
| Winsor, K | 1 |
| Barnhill, J | 1 |
| Eckert, EM | 1 |
| Dominick, KC | 1 |
| Pedapati, EV | 1 |
| Wink, LK | 2 |
| Shaffer, RC | 1 |
| Andrews, H | 1 |
| Choo, TH | 1 |
| Chen, C | 1 |
| Kaufmann, WE | 1 |
| Tartaglia, N | 1 |
| Berry-Kravis, EM | 1 |
| Erickson, CA | 3 |
| Magalotti, SR | 1 |
| Neudecker, M | 1 |
| Zaraa, SG | 1 |
| McVoy, MK | 1 |
| Blader, JC | 2 |
| Pliszka, SR | 1 |
| Kafantaris, V | 2 |
| Foley, CA | 1 |
| Carlson, GA | 1 |
| Crowell, JA | 1 |
| Bailey, BY | 1 |
| Sauder, C | 1 |
| Daviss, WB | 1 |
| Sinha, C | 1 |
| Matthews, TL | 1 |
| Margulies, DM | 1 |
| Cortese, S | 1 |
| Novins, DK | 1 |
| Mosheva, M | 1 |
| Dar, N | 1 |
| Rima Madi, L | 1 |
| Weizman, A | 2 |
| Gothelf, D | 1 |
| Deb, S | 6 |
| Aimola, L | 2 |
| Leeson, V | 2 |
| Bodani, M | 2 |
| Li, L | 2 |
| Weaver, T | 2 |
| Sharp, D | 2 |
| Bassett, P | 1 |
| Crawford, M | 5 |
| Valadas, MTTRT | 1 |
| Bravo, LEA | 1 |
| Reeves, S | 1 |
| Bertrand, J | 1 |
| Uchida, H | 1 |
| Yoshida, K | 1 |
| Otani, Y | 1 |
| Ozer, M | 1 |
| Liu, KY | 1 |
| Bramon, E | 1 |
| Bies, R | 1 |
| Pollock, BG | 1 |
| Howard, R | 1 |
| Vaudreuil, C | 1 |
| Farrell, A | 1 |
| Wozniak, J | 1 |
| Nuntamool, N | 1 |
| Ngamsamut, N | 1 |
| Vanwong, N | 1 |
| Puangpetch, A | 1 |
| Chamnanphon, M | 1 |
| Hongkaew, Y | 1 |
| Limsila, P | 1 |
| Suthisisang, C | 1 |
| Wilffert, B | 1 |
| Sukasem, C | 1 |
| Loy, JH | 2 |
| Merry, SN | 2 |
| Hetrick, SE | 2 |
| Stasiak, K | 2 |
| Masi, G | 1 |
| Manfredi, A | 1 |
| Nieri, G | 1 |
| Muratori, P | 1 |
| Pfanner, C | 1 |
| Milone, A | 1 |
| Barterian, JA | 1 |
| Arnold, LE | 15 |
| Brown, NV | 7 |
| Farmer, CA | 9 |
| Williams, C | 2 |
| Findling, RL | 14 |
| Kolko, DJ | 5 |
| Bukstein, OG | 7 |
| Molina, BSG | 2 |
| Townsend, L | 2 |
| Aman, MG | 15 |
| Anagnostou, E | 1 |
| Ostinelli, EG | 1 |
| Hussein, M | 1 |
| Ahmed, U | 1 |
| Rehman, FU | 1 |
| Miramontes, K | 1 |
| Adams, CE | 1 |
| Joseph, HM | 1 |
| Farmer, C | 1 |
| Kipp, H | 5 |
| Kolko, D | 1 |
| Aman, M | 2 |
| McGinley, J | 1 |
| Gadow, KD | 10 |
| Khan, S | 2 |
| Down, J | 1 |
| Aouira, N | 1 |
| Bor, W | 1 |
| Haywood, A | 1 |
| Littlewood, R | 1 |
| Heussler, H | 1 |
| McDermott, B | 1 |
| Scruth, E | 1 |
| Frank, GK | 1 |
| Carroll, D | 1 |
| Hallett, V | 1 |
| McDougle, CJ | 7 |
| McCracken, JT | 3 |
| Tierney, E | 4 |
| Sukhodolsky, DG | 2 |
| Lecavalier, L | 2 |
| Handen, BL | 1 |
| Swiezy, N | 2 |
| Johnson, C | 2 |
| Bearss, K | 2 |
| Vitiello, B | 5 |
| Scahill, L | 7 |
| Volavka, J | 5 |
| Czobor, P | 4 |
| Citrome, L | 5 |
| Van Dorn, RA | 1 |
| Molina, BS | 7 |
| McNamara, NK | 7 |
| Rundberg-Rivera, EV | 5 |
| Li, X | 3 |
| Schneider, J | 5 |
| Butter, EM | 3 |
| Baker, J | 1 |
| Sprafkin, J | 2 |
| Rice, RR | 5 |
| Bangalore, SS | 3 |
| Austin, AB | 2 |
| Buchan-Page, KA | 5 |
| Hurt, EA | 3 |
| Grondhuis, SN | 2 |
| Adler, BA | 1 |
| Early, M | 1 |
| Shaffer, R | 1 |
| Minshawi, N | 1 |
| Elbe, D | 1 |
| Barr, AM | 1 |
| Honer, WG | 1 |
| Procyshyn, RM | 1 |
| Ding, J | 1 |
| Gadit, AM | 1 |
| Jensen, PS | 1 |
| Kipp, HL | 1 |
| Baker, JL | 1 |
| Takeuchi, D | 1 |
| Ono, T | 1 |
| Wada, Y | 1 |
| Marrus, N | 1 |
| Underwood-Riordan, H | 1 |
| Randall, F | 1 |
| Zhang, Y | 1 |
| Constantino, JN | 1 |
| Corbett, A | 1 |
| Burns, A | 1 |
| Ballard, C | 2 |
| Phizackerley, D | 1 |
| Kolko, DG | 1 |
| Bukstein, O | 2 |
| McNamara, N | 1 |
| Bangalore, S | 1 |
| Buchan-Page, K | 2 |
| Rice, R | 2 |
| Townsend, LD | 1 |
| Molina, BB | 1 |
| Michel, C | 1 |
| Austin, A | 1 |
| Rettiganti, M | 1 |
| Nagaraja, HN | 1 |
| Hollway, JA | 1 |
| McCracken, J | 1 |
| Hellings, J | 1 |
| Posey, DJ | 2 |
| Swiezy, NB | 1 |
| Ghuman, J | 1 |
| Grados, M | 1 |
| Shah, B | 2 |
| Fragoso, VM | 1 |
| Hoppe, LY | 1 |
| de Araújo-Jorge, TC | 1 |
| de Azevedo, MJ | 1 |
| Campos, JD | 1 |
| Cortez, CM | 1 |
| de Oliveira, GM | 1 |
| Ji, NY | 1 |
| Levine, SZ | 1 |
| Kodesh, A | 1 |
| Goldberg, Y | 1 |
| Reichenberg, A | 1 |
| Furukawa, TA | 1 |
| Kolevzon, A | 1 |
| Leucht, S | 1 |
| Butter, E | 3 |
| Epstein, JN | 1 |
| Grau, K | 1 |
| Plener, PL | 1 |
| Gahr, M | 1 |
| Denzer, C | 1 |
| Freudenmann, RW | 1 |
| Gary, DS | 1 |
| Kaplin, DB | 1 |
| Sultzer, DL | 2 |
| Davis, SM | 1 |
| Tariot, PN | 1 |
| Dagerman, KS | 1 |
| Lebowitz, BD | 1 |
| Lyketsos, CG | 1 |
| Rosenheck, RA | 1 |
| Hsiao, JK | 1 |
| Lieberman, JA | 2 |
| Schneider, LS | 1 |
| Stigler, KA | 1 |
| Wadoo, O | 1 |
| Chalhoub, N | 1 |
| Schwartzer, JJ | 1 |
| Connor, DF | 2 |
| Morrison, RL | 1 |
| Ricci, LA | 2 |
| Melloni, RH | 2 |
| Vloeberghs, E | 1 |
| Coen, K | 1 |
| Van Dam, D | 1 |
| De Deyn, PP | 4 |
| Kline, AE | 1 |
| Hoffman, AN | 1 |
| Cheng, JP | 1 |
| Zafonte, RD | 1 |
| Massucci, JL | 1 |
| Handen, B | 1 |
| Dziura, J | 1 |
| Sukhodolsky, D | 1 |
| Mulick, J | 1 |
| Stigler, K | 1 |
| Ritz, L | 1 |
| Wagner, A | 1 |
| Sekiguchi, K | 1 |
| Yamaguchi, T | 1 |
| Tabuchi, M | 1 |
| Ikarashi, Y | 1 |
| Kase, Y | 1 |
| Kálmán, J | 1 |
| Kálmán, S | 1 |
| Pákáski, M | 1 |
| Tyrer, P | 4 |
| Oliver-Africano, P | 3 |
| Romeo, R | 2 |
| Knapp, M | 3 |
| Dickens, S | 2 |
| Bouras, N | 3 |
| Ahmed, Z | 3 |
| Cooray, S | 3 |
| Murphy, D | 2 |
| Hare, M | 3 |
| Meade, M | 3 |
| Reece, B | 3 |
| Kramo, K | 2 |
| Bhaumik, S | 3 |
| Harley, D | 3 |
| Regan, A | 3 |
| Thomas, D | 2 |
| Rao, B | 3 |
| Karatela, S | 3 |
| Lenôtre, L | 2 |
| Watson, J | 2 |
| Soni, A | 2 |
| Eliahoo, J | 2 |
| North, B | 2 |
| Pasini, A | 1 |
| D'Agati, E | 1 |
| Casarelli, L | 1 |
| Curatolo, P | 1 |
| Kalapatapu, RK | 1 |
| Schimming, C | 2 |
| Landreville, P | 1 |
| Leblanc, V | 1 |
| Piachaud, J | 1 |
| Ade Thomas, D | 1 |
| Dzendrowskyj, T | 1 |
| Araki, S | 1 |
| Ohji, T | 1 |
| Shiota, N | 1 |
| Dobashi, K | 1 |
| Shimono, M | 1 |
| Shirahata, A | 1 |
| Rothermel, B | 1 |
| Poustka, L | 1 |
| Banaschewski, T | 1 |
| Becker, K | 1 |
| Klampfl, K | 1 |
| Taurines, R | 1 |
| Preuss, A | 1 |
| Burger, R | 1 |
| Rothenhöfer, S | 1 |
| Wewetzer, Ch | 1 |
| Pfuhlmann, B | 1 |
| Fegert, J | 1 |
| Gerlach, M | 1 |
| Mehler-Wex, C | 1 |
| Guénolé, F | 1 |
| Amore, M | 1 |
| Bertelli, M | 1 |
| Villani, D | 1 |
| Tamborini, S | 1 |
| Rossi, M | 1 |
| Baker, JC | 1 |
| LeBlanc, LA | 1 |
| Janowsky, DS | 1 |
| Hu, Q | 1 |
| Buneviciute, J | 1 |
| Davis, JM | 1 |
| Makkos, Z | 1 |
| Fejes, L | 1 |
| Inczédy-Farkas, G | 1 |
| Kassai-Farkas, A | 1 |
| Faludi, G | 1 |
| Lazáry, J | 1 |
| West, AE | 1 |
| Weinstein, SM | 1 |
| Celio, CI | 1 |
| Henry, D | 1 |
| Pavuluri, MN | 1 |
| Devanand, DP | 1 |
| Mintzer, J | 1 |
| Schultz, SK | 1 |
| Andrews, HF | 1 |
| de la Pena, D | 1 |
| Gupta, S | 1 |
| Colon, S | 1 |
| Pelton, GH | 2 |
| Levin, B | 1 |
| Hartshorn, JC | 1 |
| Martino Maze, CD | 1 |
| De Smedt, G | 1 |
| Derivan, A | 1 |
| Lyons, B | 2 |
| Valdovinos, MG | 4 |
| Napolitano, DA | 1 |
| Zarcone, JR | 6 |
| Hellings, JA | 6 |
| Williams, DC | 1 |
| Schroeder, SR | 6 |
| Cesena, M | 1 |
| Gonzalez-Heydrich, J | 2 |
| Szigethy, E | 1 |
| Kohlenberg, TM | 1 |
| DeMaso, DR | 1 |
| Brodaty, H | 5 |
| Ames, D | 2 |
| Snowdon, J | 2 |
| Woodward, M | 1 |
| Kirwan, J | 1 |
| Clarnette, R | 1 |
| Lee, E | 1 |
| Grossman, F | 1 |
| Monnelly, EP | 2 |
| Ciraulo, DA | 2 |
| Knapp, C | 1 |
| Keane, T | 1 |
| Pajonk, FG | 1 |
| Schreiner, A | 3 |
| Peters, S | 1 |
| Rettig, K | 1 |
| Degner, D | 1 |
| Rüther, E | 1 |
| Diler, RS | 1 |
| Yolga, A | 1 |
| Avci, A | 1 |
| Bozikas, VP | 1 |
| Deseri, C | 1 |
| Pitsavas, S | 1 |
| Karavatos, A | 2 |
| Crosland, KA | 2 |
| Lindauer, SE | 2 |
| Zarcone, TJ | 1 |
| Nakaji, P | 1 |
| Meltzer, HS | 1 |
| Singel, SA | 1 |
| Alksne, JF | 1 |
| McDougle, C | 1 |
| Gonzalez, NM | 1 |
| Chuang, S | 1 |
| Davies, M | 1 |
| Hollway, J | 1 |
| Cronin, P | 1 |
| Koenig, K | 1 |
| Kohn, AE | 1 |
| McMahon, DJ | 1 |
| Fhager, B | 1 |
| Meiri, IM | 1 |
| Sjögren, M | 1 |
| Edman, A | 1 |
| Casey, DE | 1 |
| Daniel, DG | 1 |
| Wozniak, P | 1 |
| Kochan, LD | 1 |
| Tracy, KA | 1 |
| Hal, V | 1 |
| Fehér, L | 1 |
| Meguro, K | 1 |
| Meguro, M | 1 |
| Tanaka, Y | 1 |
| Akanuma, K | 1 |
| Yamaguchi, K | 1 |
| Itoh, M | 1 |
| Morse, PS | 1 |
| McKerchar, TL | 1 |
| Matthew Reese, R | 1 |
| Nolan, K | 1 |
| Sheitman, B | 1 |
| Lindenmayer, JP | 1 |
| McEvoy, JP | 1 |
| Cooper, TB | 1 |
| Zannino, G | 1 |
| Gargiulo, A | 1 |
| Lamenza, F | 1 |
| Marotta, MG | 1 |
| Barzotti, T | 1 |
| Silvestri, A | 1 |
| Ettorre, E | 1 |
| Marigliano, V | 1 |
| Coletti, DJ | 1 |
| Dicker, R | 1 |
| Padula, G | 1 |
| Pleak, RR | 1 |
| Alvir, JM | 1 |
| Lejeune, J | 1 |
| Larmo, I | 1 |
| Chrzanowski, W | 1 |
| Witte, R | 1 |
| Lex, A | 1 |
| Medori, R | 1 |
| Pandina, GJ | 1 |
| Fleisher, CA | 1 |
| Hsin, O | 1 |
| Raches, D | 1 |
| Bourgeois, BF | 1 |
| Biederman, J | 1 |
| Bhatara, V | 1 |
| Alshari, MG | 1 |
| Warhol, P | 1 |
| McMillin, JM | 1 |
| Bhatara, A | 1 |
| Rabinowitz, J | 2 |
| Katz, IR | 2 |
| Greenspan, A | 1 |
| Davidson, M | 2 |
| Shea, S | 1 |
| Turgay, A | 1 |
| Carroll, A | 1 |
| Schulz, M | 1 |
| Orlik, H | 1 |
| Smith, I | 1 |
| Dunbar, F | 1 |
| Kleinman, L | 1 |
| Frank, L | 1 |
| Ciesla, G | 1 |
| Rupnow, M | 1 |
| Mukaddes, NM | 1 |
| Abali, O | 1 |
| Gurkan, K | 1 |
| Hovens, JE | 1 |
| Dries, PJ | 1 |
| Melman, CT | 2 |
| Wapenaar, RJ | 1 |
| Loonen, AJ | 1 |
| Zhao, CS | 1 |
| Puurunen, K | 1 |
| Schallert, T | 1 |
| Sivenius, J | 1 |
| Jolkkonen, J | 1 |
| Benjamin, E | 1 |
| Salek, S | 1 |
| Chungh, DS | 1 |
| Kim, BN | 1 |
| Cho, SC | 1 |
| Rosin, RA | 1 |
| Raskind, MA | 1 |
| Sleeper, RB | 1 |
| Bitter, I | 1 |
| Dossenbach, M | 1 |
| LeBlanc, JC | 1 |
| Binder, CE | 1 |
| Armenteros, JL | 2 |
| Wang, JS | 1 |
| Hew, H | 1 |
| Kusumakar, V | 1 |
| Kurz, A | 2 |
| Schwalen S, S | 1 |
| Schmitt, A | 1 |
| Katz, I | 1 |
| Cohen-Mansfield, J | 1 |
| Buitelaar, J | 1 |
| Waite, J | 1 |
| Stoppe, G | 1 |
| Schmitt, AB | 1 |
| Reese, RM | 2 |
| Marquis, JG | 1 |
| Fleming, KK | 1 |
| Strous, RD | 1 |
| Kupchik, M | 1 |
| Roitman, S | 1 |
| Schwartz, S | 1 |
| Gonen, N | 1 |
| Mester, R | 1 |
| Spivak, B | 1 |
| Day, S | 1 |
| Saxena, K | 1 |
| Chang, K | 1 |
| Steiner, H | 1 |
| Zuidema, SU | 1 |
| van Iersel, MB | 1 |
| Koopmans, RT | 1 |
| Verhey, FR | 1 |
| Olde Rikkert, MG | 1 |
| Troost, PW | 1 |
| Althaus, M | 1 |
| Lahuis, BE | 1 |
| Buitelaar, JK | 3 |
| Minderaa, RB | 1 |
| Hoekstra, PJ | 1 |
| Günther, T | 1 |
| Herpertz-Dahlmann, B | 1 |
| Jolles, J | 1 |
| Konrad, K | 1 |
| Morrison, R | 1 |
| Hamilton, JD | 1 |
| Lewis, JE | 1 |
| Davalos, M | 1 |
| Morgan, S | 1 |
| Taylor, E | 1 |
| Williams White, S | 1 |
| Soliman, S | 1 |
| Haque, S | 1 |
| George, E | 1 |
| Villari, V | 1 |
| Rocca, P | 2 |
| Fonzo, V | 1 |
| Montemagni, C | 1 |
| Pandullo, P | 1 |
| Bogetto, F | 2 |
| Niederhofer, H | 1 |
| Shope, CB | 1 |
| Nolan, KA | 1 |
| Rapp, JT | 1 |
| Swanson, G | 1 |
| Dornbusch, K | 1 |
| Unwin, GL | 1 |
| Matson, JL | 1 |
| Wilkins, J | 1 |
| Oliver-Africano, PC | 1 |
| Ruedrich, SL | 1 |
| Swales, TP | 1 |
| Rossvanes, C | 1 |
| Diana, L | 1 |
| Arkadiev, V | 1 |
| Lim, K | 1 |
| Barzman, DH | 1 |
| István, S | 1 |
| Agoston, T | 1 |
| Tamás, T | 1 |
| Zoltán, J | 1 |
| Jeanblanc, W | 1 |
| Davis, YB | 1 |
| Fras, I | 1 |
| Major, LF | 1 |
| Buckley, PF | 2 |
| Ibrahim, ZY | 1 |
| Singer, B | 1 |
| Orr, B | 1 |
| Donenwirth, K | 1 |
| Brar, PS | 1 |
| Horrigan, JP | 1 |
| Barnhill, LJ | 1 |
| Demb, HB | 1 |
| Khan, BU | 1 |
| Steele, M | 1 |
| Fisman, S | 1 |
| Bernhard, R | 1 |
| Beck, NC | 1 |
| Greenfield, SR | 1 |
| Gotham, H | 1 |
| Menditto, AA | 1 |
| Stuve, P | 1 |
| Hemme, CA | 1 |
| Herrmann, N | 1 |
| Rivard, MF | 1 |
| Flynn, M | 1 |
| Ward, C | 1 |
| Rabheru, K | 1 |
| Campbell, B | 1 |
| Rodríguez-Arias, M | 1 |
| Miñarro, J | 1 |
| Aguilar, MA | 1 |
| Pinazo, J | 1 |
| Simón, VM | 1 |
| Schreier, HA | 1 |
| Cohen, SA | 1 |
| Ihrig, K | 1 |
| Lott, RS | 1 |
| Kerrick, JM | 1 |
| Holmes, JP | 1 |
| Carlson, DC | 1 |
| Cohen, DJ | 1 |
| Price, LH | 1 |
| Silver, H | 1 |
| Kushnir, M | 1 |
| Moechars, D | 1 |
| Gilis, M | 1 |
| Kuipéri, C | 1 |
| Laenen, I | 1 |
| Van Leuven, F | 1 |
| Jeste, DV | 1 |
| Mintzer, JE | 2 |
| Clyde, C | 1 |
| Napolitano, J | 1 |
| Brecher, M | 1 |
| Carroll, NB | 1 |
| Boehm, KE | 1 |
| Strickland, RT | 1 |
| Kleinsasser, BJ | 1 |
| Misra, LK | 1 |
| Bhatara, VS | 1 |
| Sanchez, JD | 1 |
| Reynolds, PL | 1 |
| Strayer, SM | 1 |
| Keck, PE | 1 |
| Strakowski, SM | 1 |
| McElroy, SL | 1 |
| Branicky, LA | 1 |
| Schluchter, MD | 1 |
| Lemon, E | 1 |
| Blumer, JL | 1 |
| Sharif, ZA | 1 |
| Raza, A | 1 |
| Ratakonda, SS | 1 |
| Bhana, N | 1 |
| Spencer, CM | 1 |
| Sandor, P | 1 |
| Stephens, RJ | 1 |
| Skrebuhhova-Malmros, T | 1 |
| Pruus, K | 1 |
| Rudissaar, R | 1 |
| Allikmets, L | 1 |
| Matto, V | 1 |
| Chengappa, KN | 1 |
| Levine, J | 1 |
| Ulrich, R | 1 |
| Parepally, H | 1 |
| Brar, JS | 1 |
| Atzert, R | 1 |
| Brienzo, R | 1 |
| Gopalani, A | 1 |
| Currier, GW | 1 |
| Cohen, S | 1 |
| Glazewski, R | 1 |
| Khan, A | 1 |
| Hirose, S | 2 |
| Ashby, CR | 1 |
| Mills, MJ | 1 |
| van der Gaag, RJ | 1 |
| Cohen-Kettenis, P | 1 |
| Vesce, J | 1 |
| Comaty, JE | 1 |
| Advokat, C | 1 |
| van Wattum, PJ | 1 |
| Aleman, A | 1 |
| Kahn, RS | 1 |
| Maneeton, N | 1 |
| Intaprasert, S | 1 |
| Srisurapanont, M | 1 |
| Heitun, OG | 1 |
| Tune, LE | 1 |
| Crandall, K | 2 |
| Wallace, D | 1 |
| Marquis, J | 1 |
| Fleming, K | 1 |
| Shores, R | 1 |
| Williams, D | 1 |
| Briken, P | 1 |
| Nika, E | 1 |
| Krausz, M | 1 |
| Naber, D | 1 |
| Marchiaro, L | 1 |
| Cocuzza, E | 1 |
| Hässler, F | 1 |
| Buchmann, J | 1 |
| Bohne, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD[NCT00794625] | Phase 4 | 270 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| Stimulant and Risperidone in Children With Severe Physical Aggression[NCT00796302] | Phase 4 | 168 participants (Actual) | Interventional | 2008-08-31 | Completed | ||
| Emotion Awareness and Skills Enhancement (EASE) Program: A Clinical Trial[NCT03432832] | 113 participants (Actual) | Interventional | 2018-01-30 | Completed | |||
| Placebo-Controlled Study of Risperidone for the Treatment of Children and Adolescents With Autism and Negative Behavioral Symptoms[NCT00005014] | Phase 3 | 101 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| Treatment of Psychosis and Agitation in Alzheimer's Disease[NCT02129348] | Phase 2 | 77 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Antipsychotic Discontinuation in Alzheimer's Disease[NCT00417482] | Phase 4 | 180 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder[NCT01867398] | 12 participants (Actual) | Observational | 2013-04-29 | Terminated | |||
| The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years[NCT00266552] | Phase 3 | 118 participants (Actual) | Interventional | Completed | |||
| Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors[NCT00065273] | Phase 3 | 50 participants | Interventional | 1998-07-31 | Completed | ||
| Risperidone in the Treatment of Behavioural and Psychological Signs and Symptoms in Dementia (BPSSD): a Multicentre, Double-blind, Placebo-controlled Parallel-group Trial[NCT00249158] | Phase 3 | 344 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.[NCT01917318] | Phase 2 | 1 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to Enrollment challenges - Single participant discontinued after placebo, no relevant outcome measure data was recorded.) | ||
| Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)[NCT01777542] | Phase 2 | 30 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Comparison of Oral Risperdal in Combination With Oral Lorazepam vs Standard Care Including Initial Conventional Neuroleptic IM Treatment, in Acute Schizophrenic Patients[NCT00249171] | Phase 4 | 226 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Assessing the Feasibility, Acceptability, and Preliminary Efficacy of an Adaptive Intervention Approach for Children With Autism and Disruptive Behavior: A Pilot Study[NCT04204226] | 42 participants (Actual) | Interventional | 2019-12-17 | Completed | |||
| Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study[NCT00261508] | Phase 3 | 80 participants (Actual) | Interventional | 1999-08-31 | Completed | ||
| Characterization of Endogenous Melatonin Profiles in Children With Autism Spectrum Disorder.[NCT00691080] | 58 participants (Actual) | Observational | 2007-09-30 | Completed | |||
| The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders[NCT02063945] | Phase 4 | 5 participants (Actual) | Interventional | 2017-02-01 | Terminated (stopped due to Major difficulties recruiting participants) | ||
| Methylphenidate for Hyperactivity and Impulsiveness in Children and Adolescents With Pervasive Developmental Disorders[NCT00025779] | 60 participants | Interventional | 2001-10-31 | Completed | |||
| Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial[NCT02725619] | 70 participants (Actual) | Interventional | 2016-04-30 | Completed | |||
| Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study[NCT02225808] | 10 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility[NCT00308360] | Phase 4 | 46 participants | Interventional | 1999-09-30 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone for Treatment of Behavioral Disturbances in Subjects With Dementia[NCT00253123] | Phase 3 | 626 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Antisocial Behavior Scale (ABS) is a 28-item scale that contains 10 Proactive Aggression items and six Reactive Aggression items. Each item is rated on a 3-point scale, ranging from 1 (Never) to 3 (Very often). Thus, scores on the Reactive Aggression subscale can range from 6 through 18; with higher scores indicating more reactive aggression. (NCT00796302)
Timeframe: Measured at baseline and Week 9
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 15.5 | 11.0 |
| Basic (Stimulant + PMT + Placebo) | 15.9 | 12.3 |
"Using this clinician rating scale the patient's improvement is scored on a 7-point scale which ranges from very much improved (1), through no change (4), to very much worse (7). This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Improvement scores are reported below." (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | ||
|---|---|---|---|
| Much or very much improved at endpoint | Minimally improved at endpoint | Unchanged or worse at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 63 | 11 | 6 |
| Basic (Stimulant + PMT + Placebo) | 58 | 22 | 3 |
Using this clinician rating scale the severity of the illness is scored from 1= normal to 7= extremely ill. This scale was used at baseline and Weeks 1, 2, 3, 4, 5, 6, 7, 8, & 9. Only endpoint (week 9 or subject's last visit) Clinical Global Impressions Scale for Severity of Illness scores are reported below. (NCT00796302)
Timeframe: Measured at endpoint visit
| Intervention | participants (Number) | |
|---|---|---|
| Normal/Borderline/Mildly ill at endpoint | Moderately/Markedly/Severely ill at endpoint | |
| Augmented (Stimulant + PMT + Risperidone) | 56 | 22 |
| Basic (Stimulant + PMT + Placebo) | 49 | 34 |
"Parent ratings of aggression and hostility on the Nisonger Child Behavior Rating Form-Typical IQ (NCBRF-TIQ) D-Total Score. The NCBRF provides 1 prosocial subscale (Positive/Social) and 6 problem behavior subscales (Conduct Problem, Oppositional Behavior, Hyperactive, Inattentive, Overly Sensitive, and Withdrawn/Dysphoric). The NCBRF has excellent internal consistency, distinguishes between controls and subjects with DBDs. Conduct Problem and Oppositional Behavior subscales map closely to DSM-IV-TR symptoms of CD and ODD; they were scored together to form a variable called the D-Total.~For the NCBRF D-Total, higher scores reflect worse behavior. Each subscale is scored by taking the rating (0 [did not occur or was not a problem] to 3 [occurred a lot or was a very severe problem]) for all component items. The D-Total score was computed by adding the 6 scores from the Oppositional subscale and the 10 items from the Conduct Problem subscale. Thus D-Total scores could range from 0-69." (NCT00796302)
Timeframe: Measured at baseline and Weeks 3, 4, 5, 6, 7, 8, 9
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | Week 8 | Week 9 | |
| Augmented (Stimulant + PMT + Risperidone) | 42.1 | 25.9 | 17.1 | 12.1 | 13.8 | 13.0 | 11.7 | 10.7 |
| Basic (Stimulant + PMT + Placebo) | 43.5 | 24.9 | 22.4 | 20.1 | 20.7 | 16.8 | 17.8 | 17.8 |
Basic Activities of Daily Living with items for 6 functions: bathing, dressing, toileting, transferring, continence, and feeding. Each item is scored as unimpaired=1, impaired=0. Total score is the measure used, range 0-6; higher scores indicate better functioning. (NCT02129348)
Timeframe: Assessed at Week 0, Week2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.3 |
| Placebo Group | 0.1 |
Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain is the measure used that combines symptoms of agitation and aggression. Frequency X Severity rating score, range 0-12. Higher score indicates more agitation and aggressive behavior. (NCT02129348)
Timeframe: Assessed at screening, Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.2 |
| Placebo Group | 2.5 |
Clinical Global Impression (CGI) Behavior Change score is the measure used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Scores ranging from 1-3 indicate improvement. Only patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 8 |
The patient is classified as a responder (score=1) if both criteria are met or as a non-responder (score=0) if both criteria are not met. The first criterion to determine responder status, NPI core score, has a scoring range 0-36; each of the three component scores for symptoms of agitation/aggression, delusions and hallucinations has a scoring range 0-12. For each symptom and the total score, higher score indicates more symptoms. The second criterion to determine responder status, Clinical Global Impression (CGI), is used to assess change in overall behavior; scoring range 1-7 with higher scores indicating worsening over time and lower scores indicating improvement over time. Only patients who met both criteria, assessed as change compared to baseline, were counted as responders; all other patients were non-responders. Patients that demonstrated improvement at week 12 were reported; scores for earlier weeks were only used to assess progress throughout the study. (NCT02129348)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| Lithium Treatment Group | 12 |
| Placebo Group | 7 |
30 item questionnaire used to assess degree of cognitive impairment. Orientation, registration, attention/calculation, recall, language, repetitions and commands are assessed. Total score is the measure used; range 0-30, higher scores indicate better global cognitive function. (NCT02129348)
Timeframe: Assessed at Screening, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.9 |
| Placebo Group | 0.9 |
Neuropsychological test used to assess a patient's cognitive ability. The patient is asked to complete small tasks such as drawing shapes and printing their name. They are also asked to remember certain names and objects, such as a cup and a spoon, and the evaluator's first name. Total score is the measure used; range 0-100, higher scores indicate better cognition. (NCT02129348)
Timeframe: Assessed at Week 0, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.1 |
| Placebo Group | -0.0 |
Simpson Angus Scale for Extrapyramidal Sign requires in-person examination to assess gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head dropping, glabella tap, tremor, and salivation. Total score is the measure used, range 0-40; higher scores indicate increased severity of signs. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | -0.0 |
| Placebo Group | 0.0 |
Treatment Emergent Symptom Scale that covers 26 somatic symptoms, each rated as present (score=1) or absent (score=0). Total score is the measure used with scoring range 0-26; higher scores indicate more somatic symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 0.6 |
| Placebo Group | 0.7 |
Young Mania Rating Scale total score is the measure used to assess symptoms that occur in mania; each item is a symptom that is rated for severity. Scoring range 0-60; higher scores indicate more severe symptoms. (NCT02129348)
Timeframe: Assessed at Week 0, Week 2, Week 4, Week 6, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 3.1 |
| Placebo Group | 1.1 |
Zarit Caregiver Burden Interview with the caregiver asked to rank 22 items on a scale with responses for each item from 'never' (score 0) to 'nearly always' (score 4). Total score is the measure used; range 0-88 with higher scores indicating greater caregiver burden. (NCT02129348)
Timeframe: Assessed at Week 0, Week 4, Week 8, Week 10, Week 12
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Lithium Treatment Group | 2.8 |
| Placebo Group | -0.4 |
The Abnormal Involuntary Movement Scale (AIMS) assesses signs of tardive dyskinesia, a movement disorder that can occur with prolonged use of antipsychotic medication. The AIMS score ranges from 0 to 35, with higher scores indicating more severe symptoms. For each subject, the change in AIMS score between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in AIMS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.03 |
| Risperidone | 0.24 |
Extrapyramidal signs, also known as Parkinsonian signs, refer to signs of tremor, rigidity, and bradykinesia (slowed movement) that are seen in Parkinson's disease. Assessment of extrapyramidal signs (EPS) were made with the use of the Simpson-Angus scale (which ranges from 1-40) with higher scores indicating more extrapyramidal signs. For each subject, the change in EPS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in EPS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.20 |
| Risperidone | 0.34 |
The MMSE assesses cognition. Scores range from 0-30, with higher scores indicating better cognition. For each subject, the change in MMSE between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in MMSE over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | -0.13 |
| Risperidone | -0.77 |
Physical Self-Maintenance Scale, which ranges from 1 to 30, with higher scores indicating WORSE functioning. For each subject, the change in PSMS between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in PSMS (worse functioning) over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.80 |
"A relapse occurred in Phase B (post-randomization) if both of the following criteria were met:~Increase in the Neuropsychiatric Inventory (NPI) core score of 30% or more OR a 5-point increase from the baseline NPI score at the end of Phase A~A score of 6 (much worse) or 7 (very much worse) on the Clinical Global Impression-Change (CGI-C) at any visit." (NCT00417482)
Timeframe: 0-16 weeks in Phase B (16-32 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Phase B Arm 1: Risperidone-Risperidone | 15 |
| Phase B Arm 2: Risperidone -Placebo | 8 |
| Phase B Arm 3: Placebo-Placebo | 24 |
Same definition and criteria as the primary outcome (NCT00417482)
Timeframe: 16-32 weeks in Phase B (32-48 weeks in study)
| Intervention | participants (Number) |
|---|---|
| Arm 1: Risperidone - Risperidone | 2 |
| Arm 2: Risperidone - Placebo | 13 |
The Treatment Emergent Symptom Scale (TESS) assesses 26 somatic symptoms. Total scores range from 0-26, with a score of 0 or 1 for each item. Higher scores indicate more somatic symptoms. For each subject, the change in TESS between week 16 and baseline (randomization) was calculated by subtraction, so that a positive value indicates an increase in TESS over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo | 0.18 |
| Risperidone | 0.21 |
For each subject, the change in weight in pounds between week 16 and randomization was calculated by subtraction, so that a positive value indicates an increase in weight over time. (NCT00417482)
Timeframe: Phase B, weeks 1-16 (study weeks 16-32)
| Intervention | pounds (Mean) |
|---|---|
| Placebo | 0.32 |
| Risperidone | 0.73 |
"Intensity of Suicidal Ideation was monitored over the course of the trial by the second section of the Columbia Suicide Severity Rating Scale (CSSRS). This section is only administered if the patient answers yes to the first section. The section consists of 5 questions that refer to the most severe level of ideation endorsed in the first section of the CSSRS. The total score ranges from 2 to 25, with a higher number indicating more intense ideation and greater risk.~Only lifetime intensity of suicidal ideation was explored as the patient had no suicidal ideation from the month prior to beginning the study to the completion of the study" (NCT01917318)
Timeframe: Baseline
| Intervention | score on a scale (Number) |
|---|---|
| Placebo / Iloperidone | 16 |
Aggression was measured by the Modified Overt Aggression Scale (MOAS).This assessment measures four types of aggressive behavior (verbal, aggression against property, autoaggression, and physical aggression) . Total scores on the MOAS range from 0-40, with a higher score indicating more aggressive behavior. (NCT01917318)
Timeframe: Randomization and 8 weeks of treatment, during both treatment periods
| Intervention | units on a scale (Number) | |||
|---|---|---|---|---|
| MOAS at randomization 1 | MOAS after 8 weeks with placebo | MOAS at randomization 2 | MOAS after 2 weeks with iloperidone treatment | |
| Placebo / Iloperidone | 1 | 0 | 0 | 0 |
"The Clinician-Administered PTSD Scale (CAPS) is a structured interview used to diagnose and assess PTSD. Part B of CAPS evaluates symptoms of re-experiencing. Part D evaluates avoidance and numbing.~CAPS-B scores range from 0 to 40 where higher scores indicate more symptoms. A score 0 means no re-experiencing symptoms.~CAPS-D scores range form 0 to 56 and higher scores indicate more symptoms. A score 0 means no avoidance or numbing symptoms.~The primary endpoint was changes in CAPS part B and D after 8 weeks of treatment." (NCT01917318)
Timeframe: Randomization and at the end of each treatment period. Placebo treatment lasted 8 weeks. Iloperidone treatment lasted 2 weeks.
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| CAPS part B at randomization 1 | CAPS part B after 8 weeks with placebo | CAPS part B at randomization 2 | CAPS part B after 2 weeks with iloperidone | CAPS part D at randomization 1 | CAPS part D after 8 weeks with placebo | CAPS part D at randomization 2 | CAPS part D after 2 weeks with iloperidone | |
| Placebo / Iloperidone | 20 | 4 | 4 | 0 | 6 | 2 | 7 | 0 |
The presence and severity os suicidal behavior was monitored over the course of the trial by the third section of the Columbia Suicide Severity Rating Scale (CSSRS). This sections consists of questions about 5 suicidal behaviors and non-suicidal self injurious behavior and it can be answered yes or no. The number of participants who experienced suicidal behavior is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal behavior | 1 month prior ro screening | During the course of the study | |
| Placebo / Iloperidone | 0 | 0 | 0 |
The presence of suicidal ideation was monitored over the course of the trial by the first section of the Columbia Suicide Severity Rating Scale (CSSRS). This first section of the scale consists of 5 questions that can be answered yes or no. The number of participants who reported experiencing suicidal ideation is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal ideation | 1 month prior to screening | Suicidal ideation during the study | |
| Placebo / Iloperidone | 1 | 0 | 0 |
"The ABC-C is a global behavior checklist implemented for the measurement of drug and other treatment effects in populations with intellectual disability. Behavior based on 58 items that describe various behavioral problems.~Each item is rated on the parents perceived severity of the behavior. The answer options for each item are:~0 = Not a problem~= Problem but slight in degree~= Moderately serious problem~= Severe in degree~The measure is broken down into the following subscales with individual ranges as follows:~Subscale I (Irritability): 15 items, score range = 0-45 Subscale II (Lethargy): 16 items, score range = 0-48 Subscale III (Stereotypy): 7 items, score range = 0-21 Subscale IV (Hyperactivity): 16 items, score range = 0-48 Subscale V (Inappropriate Speech) was not included in the breakdown because it was not applicable (no participants in the study had verbal language)." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Subscale I | Visit 3 - First Intervention: Subscale I | Visit 5 - First Intervention: Subscale I | Visit 6 - Second Intervention: Subscale I | Visit 8 - Second Intervention: Subscale I | Visit 10 - Second Intervention: Subscale I | Follow-up: Subscale I (Irritability) | Visit 1 - First Intervention: Subscale II | Visit 3 - First Intervention: Subscale II | Visit 5 - First Intervention: Subscale II | Visit 6 - Second Intervention: Subscale II | Visit 8 - Second Intervention: Subscale II | Visit 10 - Second Intervention: Subscale II | Follow-up: Subscale II (Lethargy) | Visit 1 - First Intervention: Subscale III | Visit 3 - First Intervention: Subscale III | Visit 5 - First Intervention: Subscale III | Visit 6 - Second Intervention: Subscale III | Visit 8 - Second Intervention: Subscale III | Visit 10 - Second Intervention: Subscale III | Follow-up: Subscale III (Stereotypy) | Visit 1 - First Intervention: Subscale IV | Visit 3 - First Intervention: Subscale IV | Visit 5 - First Intervention: Subscale IV | Visit 6 - Second Intervention: Subscale IV | Visit 8 - Second Intervention: Subscale IV | Visit 10 - Second Intervention: Subscale IV | Follow-up: Subscale IV (Hyperactivity) | |
| Placebo First, Then rhIGF-1 | 9.00 | 9.00 | 7.00 | 7.00 | 4.00 | 5.00 | 3.00 | 13.00 | 11.00 | 9.00 | 11.00 | 8.00 | 6.00 | 6.00 | 13.00 | 10.00 | 11.00 | 11.00 | 10.00 | 8.00 | 8.00 | 13.00 | 12.00 | 11.00 | 11.00 | 7.00 | 10.00 | 9.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 2.00 | 4.00 | 3.00 | 5.00 | 2.00 | 8.00 | 7.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.00 | 12.00 | 10.00 | 9.00 | 11.00 | 9.00 | 9.00 | 9.00 | 8.00 | 8.00 | 6.00 | 7.00 | 4.00 | 5.00 | 5.00 |
"Remaining subscales of the ADAMS that are not primary outcome measures include: Manic/hyperactive, Depressed mood, General anxiety, Obsessive/compulsive behavior.~The range for each subscale is as follows:~Manic/Hyperactive Behavior: 0-15 Depressed Mood: 0-21 General Anxiety: 0-21 Obsessive/Compulsive Behavior: 0-9~The higher the score for each subscale, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Manic/Hyperactive | Visit 2- First Intervention: Manic/Hyperactive | Visit 3- First Intervention: Manic/Hyperactive | Visit 4- First Intervention: Manic/Hyperactive | Visit 5- First Intervention: Manic/Hyperactive | Visit 6- Second Intervention: Manic/Hyperactive | Visit 7- Second Intervention: Manic/Hyperactive | Visit 8- Second Intervention: Manic/Hyperactive | Visit 9- Second Intervention: Manic/Hyperactive | Visit 10- First Intervention: Manic/Hyperactive | Follow-up: Manic/Hyperactive Subscale | Visit 1- First Intervention: Depressed Mood | Visit 2- First Intervention: Depressed Mood | Visit 3- First Intervention: Depressed Mood | Visit 4- First Intervention: Depressed Mood | Visit 5- First Intervention: Depressed Mood | Visit 6- Second Intervention: Depressed Mood | Visit 7- Second Intervention: Depressed Mood | Visit 8- Second Intervention: Depressed Mood | Visit 9- Second Intervention: Depressed Mood | Visit 10- Second Intervention: Depressed Mood | Follow-up: Depressed Mood Subscale | Visit 1- First Intervention: General Anxiety | Visit 2- First Intervention: General Anxiety | Visit 3- First Intervention: General Anxiety | Visit 4- First Intervention: General Anxiety | Visit 5- First Intervention: General Anxiety | Visit 6- Second Intervention: General Anxiety | Visit 7- Second Intervention: General Anxiety | Visit 8- Second Intervention: General Anxiety | Visit 9- Second Intervention: General Anxiety | Visit 10- Second Intervention: General Anxiety | Follow-up: General Anxiety Subscale | Visit 1- First Intervention: Obsessive Compulsive | Visit 2- First Intervention: Obsessive Compulsive | Visit 3- First Intervention: Obsessive Compulsive | Visit 4- First Intervention: Obsessive Compulsive | Visit 5- First Intervention: Obsessive Compulsive | Visit 6- Second Intervention: Obsessive Compulsive | Visit 7- Second Intervention: Obsessive Compulsive | Visit 8- Second Intervention: Obsessive Compulsive | Visit 9- Second Intervention: Obsessive Compulsive | Visit 10- First Intervention: Obsessive Compulsive | Follow-up: Obsessive Compulsive Behavior Subscale | |
| Placebo First, Then rhIGF-1 | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 8.00 | 6.50 | 6.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 3.00 | 2.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 8.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 4.00 | 5.50 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 7.00 | 7.00 | 6.00 | 5.00 | 4.00 | 6.00 | 5.00 | 5.00 | 4.00 | 4.50 | 5.00 | 4.00 | 5.00 | 3.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 2.00 | 3.00 | 3.50 | 6.00 | 7.00 | 6.00 | 5.00 | 5.00 | 7.00 | 5.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.50 | 3.00 |
"The ADAMS is completed by the parent/caregiver/LAR and consists of 29 items which are scored on a 4-point rating scale that combines frequency and severity ratings. The instructions ask the rater to describe the individual's behavior over the last six months on the following scale: 0 if the behavior has not occurred, 1 if the behavior occurs occasionally or is a mild problem, 2 if the behavior occurs quite often or is moderate problem, or 3 if the behavior occurs a lot or is a severe problem.~The Social Avoidance subscale of the ADAMS will be used as a primary outcome measure for this trial. The range for this subscale is 0-21. The higher the subscale score, the more problematic the behavior." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.50 | 3.00 |
"Each time the patient was seen after the study intervention was initiated, the clinician compared the patient's overall clinical condition to the CGI-S score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | ||||
|---|---|---|---|---|---|
| Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
"This scale is used to judge the severity of the subject's disease prior to entry into the study. The clinician will rate the severity of behavioral symptoms at baseline on a 7-point scale from not impaired to the most impaired.~The scores that correspond to each possible grouping are as follows: 1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | units on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 3 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 8 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.50 |
"The CSBS-DP was designed to measure early communication and symbolic skills in infants and young children (that is, functional communication skills of 6 month to 2 year olds). The CSBS-DP measures skills from three composites: (a) Social (emotion, eye gaze, and communication); (b) Speech (sounds and words); and (c) Symbolic (understanding and object use) and asks about developmental milestones. The data reported are the composite scores for these three categories.~The possible scores for the three composite categories are as follows:~Social Composite = 0-48; Speech Composite = 0-40; Symbolic Composite = 0-51.~A higher score indicates more advanced abilities in that area." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Social | Visit 2: Social Composite Score | Visit 3: Social Composite Score | Visit 4: Social Composite Score | Visit 5: Social Composite Score | Visit 6 - Second Intervention: Social | Visit 7 - Second Intervention: Social | Visit 8 - Second Intervention: Social | Visit 9 - Second Intervention: Social | Visit 10 - Second Intervention: Social | Follow-up: Social Composite Score | Visit 1 - First Intervention: Speech | Visit 2 - First Intervention: Speech | Visit 3 - First Intervention: Speech | Visit 4 - First Intervention: Speech | Visit 5 - First Intervention: Speech | Visit 6 - Second Intervention: Speech | Visit 7 - Second Intervention: Speech | Visit 8 - Second Intervention: Speech | Visit 9 - Second Intervention: Speech | Visit 10 - Second Intervention: Speech | Follow-up: Speech Composite Score | Visit 1 - First Intervention: Symbolic | Visit 2 - First Intervention: Symbolic | Visit 3 - First Intervention: Symbolic | Visit 4 - First Intervention: Symbolic | Visit 5 - First Intervention: Symbolic | Visit 6 - Second Intervention: Symbolic | Visit 7 - Second Intervention: Symbolic | Visit 8 - Second Intervention: Symbolic | Visit 9 - Second Intervention: Symbolic | Visit 10 - Second Intervention: Symbolic | Follow-up: Symbolic Composite Score | |
| Placebo First, Then rhIGF-1 | 19.00 | 20.00 | 18.00 | 18.00 | 20.00 | 18.00 | 20.00 | 21.00 | 21.00 | 22.50 | 22.50 | 4.00 | 3.00 | 5.00 | 5.50 | 6.50 | 4.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 9.50 | 10.50 | 10.50 | 12.00 | 11.50 | 13.00 | 10.25 | 11.50 | 11.50 | 13.75 | 14.25 |
| rhIGF-1 First, Then Placebo | 22.00 | 24.00 | 24.00 | 24.00 | 23.00 | 28.00 | 25.00 | 27.00 | 29.00 | 27.00 | 28.00 | 7.00 | 5.00 | 8.00 | 5.00 | 8.00 | 8.50 | 7.00 | 6.50 | 5.00 | 7.25 | 6.00 | 14.00 | 14.50 | 15.00 | 14.00 | 16.50 | 18.50 | 17.00 | 17.00 | 18.00 | 17.00 | 18.00 |
"The Kerr clinical severity scale (Kerr scale) is a quantitative measure of global disease severity. The Kerr scale is a summation of individual items related to Rett syndrome phenotypic characteristics. The items are based on the severity or degree of abnormality of each characteristic on a discrete scale (0, 1, 2) with the highest level corresponding to the most severe or most abnormal presentations.~The possible range of scores is 0-48. The higher the score, the more severe the symptoms." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||
|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 10 - Second Intervention | |
| Placebo First, Then rhIGF-1 | 16.50 | 15.00 | 15.00 | 14.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 18.00 | 19.00 | 20.00 |
"The MSEL is a standardized developmental test for children ages 3 to 68 months consisting of five subscales: gross motor, fine motor, visual reception, expressive language, and receptive language.~The raw score is reported for each subscale domain. The potential score ranges are as follows:~Visual Reception: 33 items, score range=0-50, Fine Motor: 30 items, score range= 0-49, Receptive Language: 33 items, score range= 0-48, Expressive Language: 28 items, score range= 0-50. The gross motor subscale was not included in this population.~A higher raw score indicates more advanced abilities in that section." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: Visual Reception | Visit 5- First Intervention: Visual Reception | Visit 6- Second Intervention: Visual Reception | Visit 10: Visual Reception Raw Score | Visit 1- First Intervention: Fine Motor | Visit 5- First Intervention: Fine Motor | Visit 6- Second Intervention: Fine Motor | Visit 10- Second Intervention: Fine Motor | Visit 1- First Intervention: Receptive Language | Visit 5- First Intervention: Receptive Language | Visit 6- Second Intervention: Receptive Language | Visit 10- Second Intervention: Receptive Language | Visit 1- First Intervention: Expressive Language | Visit 5- First Intervention: Expressive Language | Visit 6- Second Intervention: Expressive Language | Visit 10- Second Intervention: Expressive Language | |
| Placebo First, Then rhIGF-1 | 17.00 | 26.00 | 23.00 | 28.00 | 10.00 | 9.00 | 11.00 | 9.00 | 20.00 | 30.00 | 31.00 | 31.00 | 8.00 | 9.00 | 6.00 | 8.00 |
| rhIGF-1 First, Then Placebo | 26.00 | 39.50 | 42.00 | 44.00 | 7.00 | 7.00 | 10.00 | 8.50 | 25.50 | 32.00 | 38.00 | 36.50 | 9.00 | 8.00 | 10.00 | 8.00 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 6.50 | 4.70 | 5.65 | 5.05 | 4.80 | 4.95 | 4.55 | 5.65 | 4.15 | 4.80 | 5.60 |
| rhIGF-1 First, Then Placebo | 8.80 | 4.80 | 5.35 | 5.10 | 5.15 | 5.20 | 4.65 | 5.00 | 5.15 | 5.05 | 5.08 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.75 | 4.50 | 5.85 | 5.00 | 5.00 | 5.35 | 5.50 | 5.15 | 3.80 | 4.90 | 5.15 |
| rhIGF-1 First, Then Placebo | 6.35 | 5.25 | 5.95 | 5.40 | 5.45 | 7.10 | 5.85 | 5.00 | 5.13 | 4.95 | 5.20 |
"The parent or caretaker identifies the three most troublesome, RTT-specific, target symptoms, such as inattention or breath-holding. This allows the problems that are of concern to parents and the family to be targeted in the trial. In this study the caregiver will choose three target symptoms at baseline and then rate changes in severity of each target symptom on a visual analog scale (VAS).~The VAS is a 10 cm line, where a target symptom is anchored on one end with the description the best it has ever been and on the other with the description the worst it has ever been. The parent was asked to marked on the line where they felt their child's symptoms currently fit best. This mark was measured as recorded as a numeric value from 0.00-10.00 cm. The higher the value, the worse the symptom." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 7.85 | 4.70 | 5.65 | 4.15 | 5.00 | 6.20 | 4.80 | 4.85 | 4.60 | 4.13 | 4.55 |
| rhIGF-1 First, Then Placebo | 5.70 | 5.00 | 5.20 | 5.35 | 5.10 | 5.35 | 4.95 | 5.15 | 5.25 | 4.55 | 5.10 |
"As part of each visit after the study intervention was initiated, the parent/caregiver was asked to compare the patient's overall clinical condition to the score obtained at the baseline (visit 1) visit. Based on information collected, the clinician determined if any improvement occurred on the following 7-point scale: 1=Very much improved since the initiation of treatment; 2=Much improved; 3=Minimally improved; 4=No change from baseline (the initiation of treatment); 5=Minimally worse; 6=Much worse; 7=Very much worse since the initiation of treatment.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
"The PGI-S is the parent version of the CGI-S. Parents/caregivers/LAR are asked to rate the severity of their child's symptoms at baseline on a 7-point scale from not at all impaired to the most impaired. The parents/caregivers/LAR will complete the PGI-S at each study visit.~The scores that correspond to each possible grouping are as follows:~1=Normal, not at all impaired; 2=Borderline impaired; 3=Mildly impaired; 4=Moderately impaired; 5=Markedly impaired; 6=Severely impaired; 7=The most impaired.~The possible range for reported scores is 1-7." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 |
| rhIGF-1 First, Then Placebo | 6.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 5.00 | 4.00 |
"Respiratory data was collected using non-invasive respiratory inductance plethysmography from a BioCapture® recording device. BioCapture® is a child-friendly measurement device that can record from 1 to 12 physiological signal transducers in a time-locked manner. It can be configured with the pediatric chest and abdominal plethysmography bands and the 3 lead ECG signals we plan to use for monitoring cardiac safety throughout the study. Each transducer is placed on the patient independently to provide a customized fit that yields the highest signal quality for each patient irrespective of body shape and proportion. The transducer signals captured by the BioCapture® are transmitted wirelessly to a laptop computer where all signals are displayed in real-time.~The apnea index is given as apneas/hour. Data on apneas greater than or equal to 10 seconds are displayed below. The higher the frequency of apnea, the more severe the breathing abnormality." (NCT01777542)
Timeframe: Every 10 weeks during each of the two 20-week treatment periods
| Intervention | Apneas/Hour (Median) | |||||
|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Apnea Index | Visit 3 - First Intervention: Apnea Index | Visit 5 - First Intervention: Apnea Index | Visit 6 - Second Intervention: Apnea Index | Visit 8 - Second Intervention: Apnea Index | Visit 10 - Second Intervention: Apnea Index | |
| Placebo First, Then rhIGF-1 | 7.58 | 4.80 | 6.93 | 7.90 | 7.28 | 8.91 |
| rhIGF-1 First, Then Placebo | 4.05 | 3.48 | 3.07 | 3.62 | 5.55 | 5.56 |
"The RSBQ is a parent-completed measure of abnormal behaviors typically observed in individuals with RTT. Each item, grouped into eight subscales, is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of each subscale is reported. The higher the score, the more severe the symptoms of that subscale in the participant.~The range for each subscale is as follows:~General Mood: 0-16 Body rocking and expressionless face: 0-14 Hand behaviors: 0-12 Breathing Problems: 0-10 Repetitive Face Movements: 0-8 Night-time behaviors: 0-6 Walking Standing: 0-4~The fear/anxiety subscale was used as a primary outcome measure in this study and results can be found in that section." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1- First Intervention: General Mood | Visit 2- First Intervention: General Mood | Visit 3- First Intervention: General Mood | Visit 4- First Intervention: General Mood | Visit 5- First Intervention: General Mood | Visit 6- Second Intervention: General Mood | Visit 7- Second Intervention: General Mood | Visit 8- Second Intervention: General Mood | Visit 9- Second Intervention: General Mood | Visit 10- Second Intervention: General Mood | Follow-up: General Mood | Visit 1- First Intervention: Body Rocking | Visit 2- First Intervention: Body Rocking | Visit 3- First Intervention: Body Rocking | Visit 4- First Intervention: Body Rocking | Visit 5- First Intervention: Body Rocking | Visit 6- Second Intervention: Body Rocking | Visit 7- Second Intervention: Body Rocking | Visit 8- Second Intervention: Body Rocking | Visit 9- Second Intervention: Body Rocking | Visit 10- Second Intervention: Body Rocking | Followup: Body Rocking | Visit 1- First Intervention: Hand Behaviors | Visit 2- First Intervention: Hand Behaviors | Visit 3- First Intervention: Hand Behaviors | Visit 4- First Intervention: Hand Behaviors | Visit 5- First Intervention: Hand Behaviors | Visit 6- Second Intervention: Hand Behaviors | Visit 7- Second Intervention: Hand Behaviors | Visit 8- Second Intervention: Hand Behaviors | Visit 9- Second Intervention: Hand Behaviors | Visit 10- Second Intervention: Hand Behaviors | Follow-up: Hand Behaviors | Visit 1- First Intervention: Breathing Problems | Visit 2- First Intervention: Breathing Problems | Visit 3- First Intervention: Breathing Problems | Visit 4- First Intervention: Breathing Problems | Visit 5- First Intervention: Breathing Problems | Visit 6- Second Intervention: Breathing Problems | Visit 7- Second Intervention: Breathing Problems | Visit 8- Second Intervention: Breathing Problems | Visit 9- Second Intervention: Breathing Problems | Visit 10- Second Intervention: Breathing Problems | Follow-up: Breathing Problems | Visit 1- First Intervention: Repetitive Face Movem | Visit 2- First Intervention: Repetitive Face Movem | Visit 3- First Intervention: Repetitive Face Movem | Visit 4- First Intervention: Repetitive Face Movem | Visit 5- First Intervention: Repetitive Face Movem | Visit 6- Second Intervention: Repetitive Face Mov | Visit 7- Second Intervention: Repetitive Face Mov | Visit 8- Second Intervention: Repetitive Face Mov | Visit 9- Second Intervention: Repetitive Face Mov | Visit 10- Second Intervention: Repetitive Face Mov | Follow-up: Repetitive Face Movements | Visit 1- First Intervention: Night time Behaviors | Visit 2- First Intervention: Night time Behaviors | Visit 3- First Intervention: Night time Behaviors | Visit 4- First Intervention: Night time Behaviors | Visit 5- First Intervention: Night time Behaviors | Visit 6- Second Intervention: Night time Behavior | Visit 7- Second Intervention: Night time Behavior | Visit 8- Second Intervention: Night time Behavior | Visit 9- Second Intervention: Night time Behavior | Visit 10- Second Intervention: Night time Behavior | Follow-up: Night time Behaviors | Visit 1- First Intervention: Walking/Standing | Visit 2- First Intervention: Walking/Standing | Visit 3- First Intervention: Walking/Standing | Visit 4- First Intervention: Walking/Standing | Visit 5- First Intervention: Walking/Standing | Visit 6- Second Intervention: Walking/Standing | Visit 7- Second Intervention: Walking/Standing | Visit 8- Second Intervention: Walking/Standing | Visit 9- Second Intervention: Walking/Standing | Visit 10- Second Intervention: Walking/Standing | Follow-up: Walking/Standing | |
| Placebo First, Then rhIGF-1 | 7.00 | 5.00 | 6.00 | 5.00 | 5.00 | 4.00 | 5.50 | 5.00 | 6.00 | 4.00 | 5.50 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 4.00 | 5.00 | 4.50 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 9.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.50 | 6.00 | 4.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.50 | 6.00 | 5.00 | 6.00 | 5.00 | 2.00 | 2.00 | 3.00 | 2.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 3.00 | 1.50 | 2.00 |
| rhIGF-1 First, Then Placebo | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | 2.00 | 1.00 | 2.50 | 2.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 8.00 | 8.00 | 8.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 7.00 | 9.00 | 8.50 | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 1.50 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
"The RSBQ is an informant/parent-completed measure of abnormal behaviors typically observed in individuals with RTT, which is completed by a parent/caregiver/LAR. Each item, grouped into eight domains/factors: General mood, Breathing problems, Body rocking and expressionless face, Hand behaviors, Repetitive face movements, Night-time behaviors, Fear/anxiety and Walking/standing), is scored on a Likert scale of 0-2, according to how well the item describes the individual's behavior. A score of 0 indicates the described item is not true, a score of 1 indicates the described item is somewhat or sometimes true, and a score of 2 indicates the described item is very true or often true.~The total sum of items in each subscale is reported.~For the fear/anxiety subscale, the sum total could be between 0-8. The higher the sum total score, the greater the frequency of fear/anxiety behaviors." (NCT01777542)
Timeframe: Every 5 weeks during each of the two 20-week treatment periods, and once 4 weeks after final treatment ends
| Intervention | units on a scale (Median) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention | Visit 2 - First Intervention | Visit 3 - First Intervention | Visit 4 - First Intervention | Visit 5 - First Intervention | Visit 6 - Second Intervention | Visit 7 - Second Intervention | Visit 8 - Second Intervention | Visit 9 - Second Intervention | Visit 10 - Second Intervention | Follow-up | |
| Placebo First, Then rhIGF-1 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 3.00 | 3.00 | 4.00 | 3.50 |
| rhIGF-1 First, Then Placebo | 5.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 | 3.00 | 4.00 | 3.00 | 3.00 | 3.50 |
"The VABS-II is a survey designed to assess personal and social functioning. Within each domain (Communication, Daily Living Skills, Socialization, and Motor Skills), items can given a score of 2 if the participant successfully performs the activity usually; a 1 if the participant successfully performs the activity sometimes, or needs reminders; a 0 if the participant never performs the activity, and a DK if the parent/caregiver is unsure of the participant's ability for an item.~The raw scores in each sub-domain are reported and the ranges for these are as follows: [Communication Domain], Receptive Language=0-40, Expressive Language=0-108, Written Language=0-50; [Daily Living Skills Domain], Personal=0-82, Domestic=0-48, Community=0-88; [Socialization Domain], Interpersonal Relationships=0-76, Play and Leisure Time=0-62, Coping Skills=0-60; [Motor Skills Domain]: Gross Motor Skills=0-80, Fine Motor Skills=0-72.~A higher score indicates more advanced abilities." (NCT01777542)
Timeframe: At the start and end of each 20-week treatment period
| Intervention | units on a scale (Median) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 - First Intervention: Receptive | Visit 5 - First Intervention: Receptive | Visit 6 - Second Intervention: Receptive Language | Visit 10 - Second Intervention: Receptive Language | Visit 1 - First Intervention: Expressive | Visit 5 - First Intervention: Expressive | Visit 6 - Second Intervention: Expressive Lang. | Visit 10 - Second Intervention: Expressive Lang. | Visit 1 - First Intervention: Written | Visit 5 - First Intervention: Written | Visit 6: - Second Intervention Written Language | Visit 10 - Second Intervention: Written Language | Visit 1 - First Intervention: Personal | Visit 5 - First Intervention: Personal | Visit 6 - Second Intervention: Personal | Visit 10 - Second Intervention: Personal | Visit 1 - First Intervention: Domestic | Visit 5 - First Intervention: Domestic | Visit 6 - Second Intervention: Domestic | Visit 10 - Second Intervention: Domestic | Visit 1 - First Intervention: Community | Visit 5 - First Intervention: Community | Visit 6 - Second Intervention: Community | Visit 10 - Second Intervention: Community | Visit 1 - First Intervention: Interpersonal Rel. | Visit 5 - First Intervention: Interpersonal Rel. | Visit 6 - Second Intervention: Interpersonal Rel. | Visit 10 - Second Intervention: Interpersonal Rel. | Visit 1 - First Intervention: Play and Leisure | Visit 5 - First Intervention: Play and Leisure | Visit 6 - Second Intervention: Play and Leisure | Visit 10 - Second Intervention: Play and Leisure | Visit 1 - First Intervention: Coping Skills | Visit 5 - First Intervention: Coping Skills | Visit 6 - Second Intervention: Coping Skills | Visit 10 - Second Intervention: Coping Skills | Visit 1 - First Intervention: Gross Motor | Visit 5 - First Intervention: Gross Motor | Visit 6 - Second Intervention: Gross Motor | Visit 10 - Second Intervention: Gross Motor | Visit 1 - First Intervention: Fine Motor | Visit 5 - First Intervention: Fine Motor | Visit 6 - Second Intervention: Fine Motor | Visit 10 - Second Intervention: Fine Motor | |
| Placebo First, Then rhIGF-1 | 13.00 | 15.00 | 18.00 | 20.00 | 16.00 | 17.00 | 18.00 | 20.00 | 0.00 | 0.00 | 4.00 | 6.00 | 9.00 | 10.00 | 9.00 | 10.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 2.00 | 18.00 | 18.00 | 19.00 | 20.00 | 8.00 | 11.00 | 12.00 | 11.00 | 3.00 | 2.00 | 3.00 | 4.00 | 31.00 | 34.00 | 27.00 | 27.00 | 6.00 | 6.00 | 7.00 | 5.00 |
| rhIGF-1 First, Then Placebo | 18.00 | 21.00 | 22.00 | 24.50 | 18.00 | 22.00 | 25.00 | 24.00 | 4.00 | 5.00 | 7.00 | 7.00 | 8.00 | 9.00 | 8.50 | 9.50 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 3.00 | 5.00 | 5.00 | 21.00 | 22.00 | 21.00 | 22.50 | 13.00 | 12.00 | 13.00 | 12.50 | 3.00 | 4.00 | 6.00 | 4.50 | 10.00 | 10.00 | 11.50 | 10.50 | 2.00 | 3.00 | 4.00 | 4.00 |
26 reviews available for risperidone and Aggression
| Article | Year |
|---|---|
Updates in Pharmacologic Strategies for Emotional Dysregulation in Attention Deficit Hyperactivity Disorder.
Topics: Adolescent; Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disor | 2022 |
Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Child; Conduct Disorder; Humans; In | 2022 |
Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2019 |
Psychopharmacology of Treating Explosive Behavior.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2017 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Carbamazepine; Humans; Oxcarbazepine; Psycho | 2018 |
Current pharmacotherapy options for conduct disorders in adolescents and children.
Topics: Adolescent; Aggression; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Central Nervous Sys | 2019 |
Risperidone for Psychosis-Induced Aggression or Agitation.
Topics: Aggression; Antipsychotic Agents; Humans; Psychomotor Agitation; Psychotic Disorders; Risperidone | 2019 |
Pharmacotherapy for mental health problems in people with intellectual disability.
Topics: Aggression; Anticonvulsants; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Ce | 2016 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Chil | 2008 |
[Recognition and treatment of behavioral and psychological symptoms of dementias: lessons from the CATIE-AD study].
Topics: Affect; Aggression; Antipsychotic Agents; Brain; Caregivers; Conduct Disorder; Dementia; Diagnosis, | 2008 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2012 |
Risperidone in the management of agitation and aggression associated with psychiatric disorders.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Humans; Menta | 2006 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepin | 2006 |
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Dementia; Haloperidol; Humans; Olanzapine; Psycho | 2006 |
Pharmacological treatment of pathologic aggression in children.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Central Nervous System Stimulants; Child; Drug Pr | 2008 |
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Disease Progressio | 1999 |
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Loxapine; Mental Disorders; Ol | 1999 |
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Clozapine; Depression; | 2000 |
Risperidone: a review of its use in the management of the behavioural and psychological symptoms of dementia.
Topics: Age Factors; Aggression; Animals; Antipsychotic Agents; Clinical Trials as Topic; Dementia; Dopamine | 2000 |
Atypical antipsychotic medications in the psychiatric emergency service.
Topics: Administration, Oral; Aggression; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedul | 2000 |
Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials.
Topics: Aggression; Antipsychotic Agents; Controlled Clinical Trials as Topic; Hostility; Humans; Risperidon | 2001 |
Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Multicent | 2001 |
Risperidone for the treatment of behavioral and psychological symptoms of dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Cognition | 2001 |
[Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Hostility; Humans; Olanzapine; Pirenze | 2002 |
67 trials available for risperidone and Aggression
| Article | Year |
|---|---|
Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2021 |
Risperidone versus placebo for aggression following traumatic brain injury: a feasibility randomised controlled trial.
Topics: Adult; Aggression; Brain Injuries, Traumatic; Double-Blind Method; Feasibility Studies; Humans; Lond | 2020 |
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2017 |
Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Central Nervo | 2017 |
Aggression Following Traumatic brain injury: Effectiveness of Risperidone (AFTER): study protocol for a feasibility randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Brain; Brain Injuries, Traumatic; Double- | 2018 |
Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2019 |
Examination of aggression and self-injury in children with autism spectrum disorders and serious behavioral problems.
Topics: Adolescent; Aggression; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Child; | 2014 |
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Topics: Adult; Aggression; Amisulpride; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Hostilit | 2014 |
What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2014 |
Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2015 |
Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
Topics: Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2015 |
Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Bli | 2015 |
Initial severity and efficacy of risperidone in autism: Results from the RUPP trial.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Bli | 2016 |
Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Central Nervo | 2016 |
Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2017 |
The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2017 |
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Topics: Activities of Daily Living; Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepin | 2008 |
Trial design challenges when combining medication and parent training in children with pervasive developmental disorders.
Topics: Adolescent; Aggression; Behavior Therapy; Child; Child Development Disorders, Pervasive; Combined Mo | 2009 |
Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID).
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Cost-Benefit Analysis; Dose-Response Rela | 2009 |
The treatment of challenging behaviour in intellectual disabilities: cost-effectiveness analysis.
Topics: Adult; Aggression; Antipsychotic Agents; Combined Modality Therapy; Cost-Benefit Analysis; Double-Bl | 2009 |
Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities.
Topics: Adult; Aggression; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Evid | 2010 |
Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Female; Humans; Intellectual Disability; L | 2011 |
Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.
Topics: Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Attention Deficit and Disruptive Beh | 2011 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Relapse risk after discontinuation of risperidone in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Double-Blind Method; F | 2012 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Comorb | 2002 |
Multimodal evaluation of risperidone for destructive behavior: functional analysis, direct observations, rating scales, and psychiatric impressions.
Topics: Adult; Aggression; Antipsychotic Agents; Autistic Disorder; Coffin-Lowry Syndrome; Cross-Over Studie | 2002 |
A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases; Dementia, Vascula | 2003 |
Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder.
Topics: Aggression; Antipsychotic Agents; Double-Blind Method; Humans; Irritable Mood; Middle Aged; Psychiat | 2003 |
[Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis].
Topics: Acute Disease; Adult; Aggression; Antipsychotic Agents; Female; Humans; Male; Prospective Studies; P | 2003 |
Use of functional analysis methodology in the evaluation of medication effects.
Topics: Adult; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autist | 2003 |
Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials.
Topics: Adolescent; Adult; Affect; Aggression; Autistic Disorder; Child; Clinical Trials as Topic; Dopamine | 2003 |
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Drug Therapy, Combination; H | 2004 |
Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; | 2004 |
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Huma | 2004 |
Lithium treatment of acute mania in adolescents: a placebo-controlled discontinuation study.
Topics: Acute Disease; Adolescent; Aggression; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Bri | 2004 |
Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aggression; Antipsy | 2004 |
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Dementia, Vascular; Female; Hum | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; | 2004 |
Psychometric performance of an assessment scale for strain in nursing care: the M-NCAS.
Topics: Aged; Aggression; Alzheimer Disease; Australia; Dementia, Vascular; Double-Blind Method; Female; Hum | 2004 |
Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study.
Topics: Adolescent; Adult; Aged; Aggression; Anti-Anxiety Agents; Antipsychotic Agents; Clopenthixol; Drug T | 2005 |
Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Ch | 2005 |
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Clozapine; Cohort Studies; Dibenzothiazepi | 2005 |
Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Child; Child, | 2005 |
Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice.
Topics: Aged; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Delusions; Dementia; Female; Humans; | 2005 |
[Changeover to risperidone after treatment with conventional low potency neuroleptics in dementia patients. An observation study during usage].
Topics: Aged; Aggression; Antipsychotic Agents; Behavior; Dementia; Dose-Response Relationship, Drug; Female | 2006 |
A crossover study of risperidone in children, adolescents and adults with mental retardation.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Studies; D | 2006 |
Neuropsychological effects of risperidone in children with pervasive developmental disorders: a blinded discontinuation study.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention; Child; Child Behavior Disorders; Child Deve | 2006 |
Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2007 |
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Basal Ganglia Disea | 2008 |
Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
Topics: Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Diarrhea; Drug Therapy, Combination; Femal | 2007 |
Antipsychotic drugs for aggression in intellectual disability.
Topics: Aggression; Antipsychotic Agents; Haloperidol; Humans; Intellectual Disability; Risperidone | 2008 |
Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.
Topics: Adult; Aged; Aggression; Antipsychotic Agents; Female; Haloperidol; Humans; Male; Mental Competency; | 2008 |
Aggression and schizophrenia: efficacy of risperidone.
Topics: Adult; Aggression; Analysis of Variance; Antipsychotic Agents; Female; Humans; Longitudinal Studies; | 1997 |
Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility.
Topics: Adult; Aggression; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Forensic Psy | 1997 |
Risperidone for the treatment of behavioral disturbances in dementia: a case series.
Topics: Aged; Aged, 80 and over; Aggression; Antipsychotic Agents; Behavioral Symptoms; Delusions; Dementia; | 1998 |
Risperidone for young children with mood disorders and aggressive behavior.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; | 1998 |
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Aggression; Antipsychotic Agents; Autistic Disorder; Child Developme | 1998 |
Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Basal Ganglia Diseases | 1999 |
Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Female; Hospitalization; Humans; Intellectual D | 2000 |
A double-blind pilot study of risperidone in the treatment of conduct disorder.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Conduct Disorder; Dose-Response Relationship, D | 2000 |
Effectiveness of ECT combined with risperidone against aggression in schizophrenia.
Topics: Adult; Aggression; Antipsychotic Agents; Combined Modality Therapy; Electroconvulsive Therapy; Human | 2001 |
A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; B | 2001 |
Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Stud | 2001 |
Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures.
Topics: Adolescent; Adult; Aged; Aggression; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Do | 2001 |
Treatment of borderline personality disorder with risperidone.
Topics: Adult; Aggression; Antipsychotic Agents; Borderline Personality Disorder; Dopamine Antagonists; Fema | 2002 |
94 other studies available for risperidone and Aggression
| Article | Year |
|---|---|
Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents; Antipsychotic Agents; Child; Comorbidity; Cros | 2019 |
Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment.
Topics: Aggression; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2021 |
Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges.
Topics: Aggression; Antidepressive Agents; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivi | 2020 |
De Clérambault's syndrome revisited: a case report of Erotomania in a male.
Topics: Aged; Aggression; Delusions; Female; Humans; Male; Middle Aged; Prognosis; Risperidone; Syndrome | 2020 |
Towards safer risperidone prescribing in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Humans; Psychotic Disorders; Risperidone | 2021 |
Pharmacogenomics and Efficacy of Risperidone Long-Term Treatment in Thai Autistic Children and Adolescents.
Topics: Adolescent; Adolescent Behavior; Age Factors; Aggression; Autistic Disorder; Chi-Square Distribution | 2017 |
An 11-year-old boy with Asperger's disorder presenting with aggression.
Topics: Aggression; Antipsychotic Agents; Asperger Syndrome; Behavior Control; Child; Child Behavior; Dose-R | 2013 |
Not just another antipsychotic-for-conduct-problems trial.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Child; Child D | 2015 |
Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
Topics: Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Attention Def | 2014 |
Psychosis with Huntington's disease: role of antipsychotic medications.
Topics: Aggression; Antipsychotic Agents; Humans; Huntington Disease; Male; Middle Aged; Psychotic Disorders | 2014 |
TOSCA: no longer just an opera.
Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous Sys | 2014 |
Case of neuroleptic malignant syndrome with diffuse neurofibrillary tangles with calcification.
Topics: Aged; Aggression; Antipsychotic Agents; Diffuse Neurofibrillary Tangles with Calcification; Humans; | 2015 |
Lack of effect of risperidone on core autistic symptoms: data from a longitudinal study.
Topics: Aggression; Autistic Disorder; Child; Child, Preschool; Female; Humans; Longitudinal Studies; Male; | 2014 |
Don't use antipsychotics routinely to treat agitation and aggression in people with dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Drug Substitution; Humans; Interpersonal Relations; Long | 2014 |
Licensed indication for risperidone in dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Humans; Psychomotor Agitation; Risperidone | 2014 |
Use of haloperidol and risperidone in highly aggressive Swiss Webster mice by applying the model of spontaneous aggression (MSA).
Topics: Aggression; Animals; Exploratory Behavior; Haloperidol; Male; Mice; Models, Animal; Motor Activity; | 2016 |
Mild Hypothermia in a Child with Low-Dose Risperidone.
Topics: Aggression; Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Comb | 2017 |
Risperidone-induced sexual dysfunction in a prepubertal child - a case report.
Topics: Aggression; Anger; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Human | 2009 |
Repeated risperidone administration during puberty prevents the generation of the aggressive phenotype in a developmentally immature animal model of escalated aggression.
Topics: Age Factors; Aggression; Animals; Animals, Newborn; Antipsychotic Agents; Behavior, Animal; Body Wei | 2008 |
Validation of the APP23 transgenic mouse model of Alzheimer's disease through evaluation of risperidone treatment on aggressive behaviour.
Topics: Aggression; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antipsychotic Agents; Data I | 2008 |
Chronic administration of antipsychotics impede behavioral recovery after experimental traumatic brain injury.
Topics: Aggression; Analysis of Variance; Animals; Antipsychotic Agents; Behavior, Animal; Brain Injuries; H | 2008 |
Effects of yokukansan, a traditional Japanese medicine, on aggressiveness induced by intracerebroventricular injection of amyloid beta protein into mice.
Topics: Aggression; Amyloid beta-Peptides; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Drug | 2009 |
Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome.
Topics: Abnormalities, Multiple; Adolescent; Aggression; Animals; Antipsychotic Agents; Chromosome Deletion; | 2010 |
Update on neuropsychiatric symptoms of dementia: antipsychotic use.
Topics: Aged; Aggression; Antipsychotic Agents; Aripiprazole; Dementia; Geriatric Psychiatry; Humans; Pipera | 2009 |
Older adult's acceptability ratings of treatments for verbal agitation in persons with dementia.
Topics: Aged; Aged, 80 and over; Aggression; Aging; Behavior Therapy; Dementia; Female; Humans; Male; Neurop | 2010 |
Risperidone and dementia-related aggression: new indication. A last resort, no better than haloperidol.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dementia; Drug Approval; Europe; France; | 2009 |
Successful risperidone treatment for behavioral disturbances in Prader-Willi syndrome.
Topics: Aggression; Antipsychotic Agents; Body Mass Index; Body Weight; Child; Child Behavior Disorders; Chr | 2010 |
[Bipolar disorders as co-morbidity in childhood and adolescence--underdiagnosed or overinterpreted? Therapy of a 14-year-old boy with hyperkinetic conduct disorder and hypomania].
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; A | 2010 |
Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy.
Topics: Adolescent; Age Factors; Aggression; Antipsychotic Agents; Child; Child Behavior Disorders; Disrupti | 2010 |
[Oniric activity in the onset of psychosis: the dreams of a schizophrenic].
Topics: Aggression; Antipsychotic Agents; Cognition Disorders; Delusions; Dreams; Female; Humans; Neuropsych | 2010 |
Acceptability of interventions for aggressive behavior in long-term care settings: comparing ratings and hierarchical selection.
Topics: Aggression; Attitude of Health Personnel; Behavior Therapy; Health Services for the Aged; Humans; Lo | 2011 |
Minimum effective and relapse-associated doses of risperidone and olanzapine in aggressive, intellectually disabled adults.
Topics: Adult; Age Factors; Aggression; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; I | 2011 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diben | 2011 |
Postictal psychosis: implications for nursing.
Topics: Aged; Aggression; Anticonvulsants; Antipsychotic Agents; Epilepsy, Complex Partial; Female; Humans; | 2013 |
A case series of eight aggressive young children treated with risperidone.
Topics: Aggression; Antipsychotic Agents; Brain; Child; Child Behavior Disorders; Child, Preschool; Electroe | 2002 |
Risperidone-induced obsessive-compulsive symptoms in two children.
Topics: Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Female; Huma | 2003 |
Antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia.
Topics: Adult; Aggression; Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male | 2003 |
Improvement of aggressive and antisocial behavior after resection of temporal lobe tumors.
Topics: Adolescent; Aggression; Anticonvulsants; Antipsychotic Agents; Brain Neoplasms; Child Behavior Disor | 2003 |
Treatment of aggressive behavior in dementia with the anticonvulsant topiramate: a retrospective pilot study.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Dose- | 2003 |
[Experience with Risperidone in the treatment of institutionalized mentally retarded patients, with special reference to treatment of aggressive states].
Topics: Adult; Aged; Aggression; Antipsychotic Agents; Dopamine Antagonists; Female; Humans; Hungary; Instit | 2004 |
Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis.
Topics: Adult; Aggression; Antipsychotic Agents; Child; Developmental Disabilities; Female; Humans; Male; Ra | 2004 |
The management of psychogeriatric patient.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Ag | 2004 |
No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; | 2004 |
Coexistent hypothyroidism, psychosis, and severe obsessions in an adolescent: a 10-year follow-up.
Topics: Adolescent; Aggression; Antipsychotic Agents; Fluvoxamine; Hospitalization; Humans; Hypothyroidism; | 2004 |
Short-term efficacy and safety of risperidone in young children with autistic disorder (AD).
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Diagnostic and Statist | 2004 |
Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury.
Topics: Affect; Aggression; Aging; Animals; Antidepressive Agents; Antipsychotic Agents; Behavior, Animal; B | 2005 |
Stimulant-atypical antipsychotic interaction and acute dystonia.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Bipolar | 2005 |
Neuroleptic malignant syndrome due to three atypical antipsychotics in a child.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Temperature; Child; Dibenz | 2005 |
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
Topics: Aged; Aggression; Alzheimer Disease; Amines; Antipsychotic Agents; Benzodiazepines; Cyclohexanecarbo | 2005 |
Antipsychotic dose-sparing effect with addition of memantine.
Topics: Aged; Aggression; Alzheimer Disease; Antipsychotic Agents; Dopamine Agents; Drug Therapy, Combinatio | 2005 |
Factor analysis of the Cohen-Mansfield Agitation Inventory in three large samples of nursing home patients with dementia and behavioral disturbance.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Cross-Sectional Studie | 2005 |
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weig | 2006 |
Duration of risperidone treatment for BPSD.
Topics: Aged; Aggression; Antipsychotic Agents; Dementia; Drug Administration Schedule; Female; Humans; Male | 2006 |
Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series.
Topics: Adolescent; Aggression; Antipsychotic Agents; Bipolar Disorder; Child; Female; Follow-Up Studies; Hu | 2006 |
[Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics?].
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Controlled Clinical Trials as | 2006 |
The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention; Attention Deficit and Disruptive Behavior D | 2006 |
Risperidone exerts potent anti-aggressive effects in a developmentally immature animal model of escalated aggression.
Topics: Age Factors; Aggression; Analysis of Variance; Animals; Antipsychotic Agents; Cricetinae; Disease Mo | 2007 |
The practical search.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Evidence-Based | 2007 |
Antipsychotic drugs in children with autism.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Humans; Risper | 2007 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety; Asperger Syndrome; Attention Deficit Disorder | 2008 |
Stalking and Huntington's disease: a neurobiological link?
Topics: Aggression; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Female; Fluvoxamine; For | 2007 |
Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2).
Topics: Abnormalities, Multiple; Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder wi | 2007 |
Temporary increases in problem behavior and sleep disruption following decreases in medication: a descriptive analysis of conditional rates.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Female; Human | 2007 |
Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey.
Topics: Adult; Aggression; Antipsychotic Agents; Attitude of Health Personnel; Autistic Disorder; Carbamazep | 2008 |
Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.
Topics: Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Body Weight; Dibenzothiazepines; Dose-Resp | 2008 |
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
Topics: Adult; Aggression; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzo | 2007 |
How do I decide whether or not to use medication for my child with autism? Should I try behavior therapy first?
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Behavior Therapy; Child; Clinical Trials as Top | 2008 |
Risperidone for treating dementia-associated aggression.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Dementia; Dementia, Vascular; Female; Humans | 1995 |
Clinical experience with risperidone.
Topics: Adolescent; Aggression; Antipsychotic Agents; Bipolar Disorder; Child; Child Behavior Disorders; Dos | 1995 |
Risperidone and explosive aggressive autism.
Topics: Activities of Daily Living; Adolescent; Adult; Aggression; Antipsychotic Agents; Autistic Disorder; | 1997 |
Risperidone in young children with pervasive developmental disorders and other developmental disabilities.
Topics: Aggression; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Preschool; Huma | 1996 |
Brief report: risperidone for severely disturbed behavior and tardive dyskinesia in developmentally disabled adults.
Topics: Adult; Aggression; Antipsychotic Agents; Comorbidity; Dose-Response Relationship, Drug; Drug Adminis | 1997 |
Bipolar disorder in children and adolescents: current challenges.
Topics: Adolescent; Aggression; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Clom | 1997 |
Can risperidone be antidepressive and also inhibit aggression?
Topics: Aggression; Antipsychotic Agents; Depressive Disorder; Humans; Risperidone | 1997 |
Effects of risperidone and SCH 23390 on isolation-induced aggression in male mice.
Topics: Aggression; Animals; Benzazepines; Depression, Chemical; Dopamine Antagonists; Dopamine D2 Receptor | 1998 |
Risperidone for aggression and self-injurious behavior in adults with mental retardation.
Topics: Adult; Aggression; Antipsychotic Agents; Behavior Therapy; Combined Modality Therapy; Female; Humans | 1998 |
Treatment of aggression in schizophrenia.
Topics: Adult; Aggression; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Risperidone; Schizophreni | 1998 |
Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aggression; Amyloid beta-Protein Precursor; Animals; Behavio | 1998 |
Risperidone effects on irritable aggression in posttraumatic stress disorder.
Topics: Aggression; Anger; Antipsychotic Agents; Combat Disorders; Dose-Response Relationship, Drug; Humans; | 1999 |
Chorea and tardive dyskinesia in a patient taking risperidone.
Topics: Adolescent; Aggression; Antipsychotic Agents; Chorea; Dyskinesia, Drug-Induced; Female; Humans; Ment | 1999 |
Risperidone in the treatment of choreiform movements and aggressiveness in a child with "PANDAS".
Topics: Aggression; Antipsychotic Agents; Autoimmune Diseases; Child; Child Behavior Disorders; Chorea; Huma | 1999 |
Neuroleptics for behavioral symptoms of dementia.
Topics: Aggression; Antipsychotic Agents; Dementia; Evidence-Based Medicine; Humans; Mental Disorders; Resea | 2000 |
Comparative efficacy of risperidone and clozapine in the treatment of patients with refractory schizophrenia or schizoaffective disorder: a retrospective analysis.
Topics: Adult; Aggression; Clozapine; Drug Administration Schedule; Humans; Male; Middle Aged; Psychiatric S | 2000 |
Risperidone treatment of aggressive behavior in children with Tourette syndrome.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Child, Preschool; Female; Humans; Male; Retrosp | 2000 |
The serotonin 5-HT(2A) receptor subtype does not mediate apomorphine-induced aggressive behaviour in male Wistar rats.
Topics: Aggression; Animals; Apomorphine; Behavior, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antag | 2000 |
Impact of risperidone on seclusion and restraint at a state psychiatric hospital.
Topics: Adult; Aged; Aggression; Cohort Studies; Female; Hospitals, Psychiatric; Hospitals, State; Humans; M | 2000 |
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
Topics: Aggression; Antipsychotic Agents; Diet; Dose-Response Relationship, Drug; Energy Intake; Humans; Int | 2001 |
Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone.
Topics: Adult; Aggression; Antipsychotic Agents; Antisocial Personality Disorder; Disruptive, Impulse Contro | 2001 |
Antiaggressive action of atypical antipsychotics in patients with schizophrenia.
Topics: Aggression; Antipsychotic Agents; Benzodiazepines; Humans; Male; Olanzapine; Pirenzepine; Risperidon | 2001 |
Valproic acid and risperidone.
Topics: Aggression; Antipsychotic Agents; Child; Child Behavior Disorders; Dose-Response Relationship, Drug; | 2001 |
Risperidone for controlling aggressive behavior in a mentally retarded child: a case report.
Topics: Aggression; Antipsychotic Agents; Child; Humans; Intellectual Disability; Male; Risperidone | 2001 |
[Risperidone as a tool to control hard aggression].
Topics: Adolescent; Adult; Aggression; Anticonvulsants; Antipsychotic Agents; Child; Child Behavior Disorder | 2001 |
[Possibilities and limits of treatment of aggressive behavior in patients with mental retardation with risperidone].
Topics: Adult; Aggression; Antipsychotic Agents; Female; Follow-Up Studies; Humans; Intellectual Disability; | 2002 |